Previous Article | Next Article 
Journal of Virology, March 2000, p. 2567-2583, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Efficient Gene Transfer into Human CD34+ Cells by
a Retargeted Adenovirus Vector
Dmitry M.
Shayakhmetov,1
Thalia
Papayannopoulou,2
George
Stamatoyannopoulos,1 and
André
Lieber1,*
Division of Medical
Genetics1 and Division of
Hematology,2 Department of Medicine,
University of Washington, Seattle, Washington 98195
Received 3 September 1999/Accepted 5 December 1999
 |
ABSTRACT |
Efficient infection with adenovirus (Ad) vectors based on serotype
5 (Ad5) requires the presence of coxsackievirus-adenovirus receptors
(CAR) and
v integrins on cells. The paucity of these cellular receptors is thought to be a limiting factor for Ad gene transfer into hematopoietic stem cells. In a systematic approach, we
screened different Ad serotypes for interaction with noncycling human
CD34+ cells and K562 cells on the level of virus
attachment, internalization, and replication. From these studies,
serotype 35 emerged as the variant with the highest tropism for
CD34+ cells. A chimeric vector (Ad5GFP/F35) was generated
which contained the short-shafted Ad35 fiber incorporated into an Ad5
capsid. This substitution was sufficient to transplant all infection
properties from Ad35 to the chimeric vector. The retargeted, chimeric
vector attached to a receptor different from CAR and entered cells by an
v integrin-independent pathway. In transduction
studies, Ad5GFP/F35 expressed green fluorescent protein (GFP)
in 54% of CD34+ cells. In comparison, the standard Ad5GFP
vector conferred GFP expression to only 25% of CD34+
cells. Importantly, Ad5GFP transduction, but not Ad5GFP/F35, was
restricted to a specific subset of CD34+ cells expressing
v integrins. The actual transduction efficiency was even higher than 50% because Ad5GFP/F35 viral genomes were found in GFP-negative CD34+ cell fractions,
indicating that the cytomegalovirus promoter used for transgene
expression was not active in all transduced cells. The
chimeric vector allowed for gene transfer into a broader spectrum of
CD34+ cells, including subsets with potential stem cell
capacity. Fifty-five percent of CD34+ c-Kit+
cells expressed GFP after infection with Ad5GFP/F35, whereas only
13% of CD34+ c-Kit+ cells were GFP positive
after infection with Ad5GFP. These findings represent the basis for
studies aimed toward stable gene transfer into hematopoietic stem cells.
 |
INTRODUCTION |
Human hematopoietic stem cells
(HSCs) represent an important target for gene therapy. However,
CD34+-enriched human bone marrow cells can be only poorly
transduced by the most commonly used viral vectors. HSCs are believed
to be in a quiescent state and, when induced to divide, tend to lose their stem cell capacity (4, 7, 35). Another limiting factor
for viral gene transfer into HSCs is the scarcity of corresponding cellular receptors for virus binding and/or internalization (14, 53).
Key features which make recombinant adenoviruses (Ad) an attractive
vehicle for gene transfer into hematopoietic cells include the ability
to easily prepare high-titer stocks of purified virus, the remarkable
efficiency of each step in the Ad cell/nucleus entry process leading to
high-level gene expression, and the ability to transport its
double-stranded DNA genome into the nucleus, allowing for transduction
of nondividing cells. However, transduction with first-generation,
E1/E3-deleted recombinant Ad vectors is associated with toxicity and
immune responses against Ad proteins expressed in transduced cells,
limiting the duration of transgene expression. Other important
disadvantages include the episomal status of Ad DNA in transduced cells
and the restricted tropism of recombinant Ad vectors which are based on
the well-characterized, nontumorigenic serotype 5 (Ad5)
(24).
Attachment to the cell surface of Ad5 is mediated by its fiber protein
(11; for a review, see reference
64). The fiber molecule is a homotrimer forming 12 vertices per virion. The distal, C-terminal domain of the trimeric
fiber molecule terminates in a knob, which binds with high affinity
(Ka = 109 to 1010
M
1 per site) to a specific primary receptor identified
recently as the coxsackievirus B-adenovirus receptor (CAR)
(3). After binding, Arg-Gly-Asp (RGD) motifs in the penton
base interact with cellular integrins of the
v
3 and
v
5
types which function as secondary Ad5 receptors (77). This
interaction triggers cellular internalization whereby the virion
resides within the endosome. The endosomal membrane is lysed in a
process mediated by the penton base, releasing the contents of the
endosome to the cytoplasm. During these processes, the virion is
gradually uncoated and the Ad DNA is transported into the nucleus.
The efficiency of Ad5 infection depends on CAR and integrin density
(21, 76). Binding of virions occurs with increasing cooperativity, which permits the virion to bind to several receptors simultaneously. It is known that Ad5-based vectors can infect cells
that lack CAR and/or
v integrin expression when virus is applied at very high multiplicities of infection (MOIs). Furthermore, fiberless particles demonstrate infectivity (36). In both
cases, low-affinity interactions, e.g., between penton base or hexon with cell surface proteins or receptors, may be utilized as alternative cell entry strategies. Importantly, infection with high MOIs is associated with cytotoxicity and immunogenicity in vivo and is therefore not practical for gene therapy approaches.
Due to the lack of corresponding primary and/or secondary receptors,
Ad5 gene transfer is inefficient to a number of tissues, such as
endothelia (70, 78), smooth muscle (78),
differentiated airway epithelia (82), brain tissue
(10), and peripheral blood cells (73). There are
controversial reports with regards to the ability of Ad5-based vectors
to transduce hematopoietic cells. A number of investigators noted that
bone marrow cells are refractory to Ad5 vector infection and used this
property to purge cancer cells from bone marrow (9, 12, 27, 30,
80). On the other hand, it has been shown that Ad5 vectors are
capable of infecting CD34+ cells (5, 6, 16, 19, 46,
50, 74). Drawing an overall conclusion on Ad5 vector transduction
of CD34+ cells is complicated by the fact that culture
conditions, proliferative status of CD34+ cells, transgene
promoter, and viral doses significantly differed between studies. In
some of these studies, only MOIs of 500 to 1,000 PFU/cell (6,
50) allowed for transduction; in other studies, these same MOIs
were associated with severe cytotoxicity (5, 19, 46).
Furthermore, pretreatment of CD34+ cells with cytokines
prior to infection (5, 74) may have changed the spectrum of
potential viral receptors (2, 22, 28).
Since the cell types that can be infected with Ad5 vectors are
restricted by the presence of CAR and
v integrins,
attempts were made to broaden the tropism of Ad vectors. These
approaches included complexing Ad with lipids or polycations (6,
56), using bispecific antibodies directed against Ad fiber and an
internalizing cellular receptor (75, 78), and engineering
peptide ligands into the fiber (31, 45, 76), hexon
(13), or penton (79). Most of these approaches
did not abrogate CAR tropism. The most commonly used method to retarget
Ad tropism is by swapping part or all of the fiber from one serotype to
another (10, 32, 70). There are at least 49 known Ad
serotypes, which have been classified into six subgroups (A to F),
based in part on amino acid sequence homology, hemagglutination
pattern, and oncogenic potential. The various serotypes of human Ad
show differences in tissue tropism and cause different pathologies
mostly localized to the gastrointestinal tract, respiratory tract,
genitourinary tract, or conjunctiva and cornea (25). Since
the nucleotide and amino acid sequences of fibers differ significantly
among different Ad serotypes, it has been suggested that they can
recognize different receptors (1). This implies that fiber
substitution would be sufficient to change virus tropism and has been
convincingly shown for Ad5-Ad3 chimeras (70), Ad5-Ad7
chimeras (20), and Ad5-Ad17 fiber chimeras (10).
In these studies, the Ad5 fiber or fiber knob was genetically
substituted by heterologous sequences derived from the other serotype.
Previously, we have demonstrated that inverted repeat sequences
inserted into first-generation Ad vector genomes mediate precise genomic rearrangements resulting in vector genomes devoid of all viral
genes that are efficiently packaged into functional Ad capsids (68). As a specific application of these replication
derivatives, we developed an integrating
Ad.AAV hybrid vector
devoid of all viral genes (40). The
Ad.AAV genome
contains two adeno-associated virus (AAV) inverted terminal
repeats
elements that stimulated transgene integration into cellular
DNA with a frequency comparable to that of recombinant AAV. So far,
these vectors were based on Ad5-derived capsids, which may limit their
application for gene transfer into HSCs. Our long-term goal is to adapt
integrating, gutless
Ad.AAV hybrid vectors for stable gene transfer
into HSCs by modifying their tropism. On the way to reach this goal,
the present study tested the ability of selected Ad serotypes to
interact with and transduce human CD34+ cells. Based on
these data, we generated a chimeric, first-generation Ad vector
containing heterologous fiber molecules, which allowed for efficient
transduction of human CD34+ cells with potential stem cell capacity.
 |
MATERIALS AND METHODS |
Cells and viruses.
HeLa (human cervix carcinoma; ATCC
[American Type Culture Collection] CCL-2.2), CHO (Chinese hamster
ovary; ATCC CCL-61), K562 (human erythroleukemia; ATCC 45506), HEp-2
(human larynx carcinoma, ATCC CCL-23), and 293 (human embryonic kidney;
Microbix, Toronto, Ontario, Canada) cells were maintained in Dulbecco
modified Eagle medium (DMEM)-10% fetal calf serum (FCS)-2 mM
glutamine-penicillin-streptomycin. Culture medium for CHO cells was
supplemented with 200 µM asparagine and 200 µM proline. Human
CD34+-enriched bone marrow cells were purified from
peripheral blood after mobilization using MiniMACS VS+
separation columns (Miltenyi Biotec, Auburn, Calif.) according to the
manufacturer's instructions. Aliquots were stored in liquid nitrogen.
Sixteen hours before the experiment, cells were recovered from the
frozen stock and incubated in Iscove modified Dulbecco medium
supplemented with 20% FCS, 10
4 M
-mercaptoethanol,
100 µg of DNase I per ml, 2 mM glutamine, 10 U of interleukin-3, and
50 ng of stem cell factor (SCF) or 2 ng of thrombopoietin per ml. The
purity of CD34+ preparations was verified by flow cytometry
and was consistently greater than 90%.
Ad3 (VR-3), Ad4 (VR1081), Ad5 (VR-5), Ad9 (VR1086), Ad35 (VR-716), and
Ad41 (VR-930) were purchased from the ATCC. VR-716 was purchased from
the ATCC labeled as serotype 34; however, it was found to be serotype
35 upon sequencing of the fiber region. For amplification, the
corresponding Ads were infected onto HeLa, 293, or HEp-2 cells under
conditions that prevented cross-contamination. Virus was banded in CsCl
gradients, dialyzed, and stored in aliquots as described elsewhere
(41). Plaque titering was performed as follows: confluent
293 cells plated in six-well plates were incubated for 24 h with
virus in a total volume of 1 ml; 2 weeks after infection, plaques were
counted on cultures overlaid with 1% agarose-minimal essential
medium-10% FCS.
Labeling of Ads with
methyl-3H-thymidine.
Serotypes were
labeled with [methyl-3H]thymidine as described
in detail elsewhere (59). Briefly, 5 × 107
HeLa or 293 cells were grown in 175-cm2 flasks with 15 ml
of DMEM-10% FCS and infected with wild-type Ad at an MOI of 50 or
higher. Twelve hours postinfection, 1 mCi of
[methyl-3H]thymidine (Amersham, Arlington
Heights, Ill.) was added to the medium, and cells were further
incubated at 37°C until complete cytopathic effect was observed. Then
cells were harvested, pelleted, washed once with cold
phosphate-buffered saline (PBS), and resuspended in 5 ml of PBS. Virus
was released from the cells by four freeze-thaw cycles. Cell debris was
removed by centrifugation, and viral material was subjected to
ultracentrifugation in CsCl gradients and subsequent dialysis as
previously described (41). Virus purification and dialysis
removed unincorporated radioactivity. Wild-type Ad particle concentrations were determined spectrophotometrically by measuring the
optical density at 260 nm (OD260), using the extinction
coefficient for wild-type Ad5,
260 = 9.09 × 10
13 OD ml cm virion
1 (42). The
virion-specific radioactivity was measured by a liquid scintillation
counter and was always in the range of 10
5 to
10
4 cpm per virion. For selected variants, the fiber gene
was PCR amplified and sequenced to ensure identity and the absence of cross-contamination.
Electron microscopy (EM) studies.
CsCl-banded Ad stocks were
thawed and diluted with 0.5% glutaraldehyde. Grids were prepared as
described earlier (47). After staining with 2% methylamine
tungstate (Nanoprobes, Stony Brook, N.Y.), the carbon-coated grids were
evaluated and photomicrographed with a Philips 410 electron microscope,
operated at 80 kV (final magnification, ×85,000). For each particular
Ad serotype, the number of morphologically deficient viral particles
per 100 was counted in five random fields.
Attachment and internalization assays.
The studies were
performed based on a protocol published elsewhere (77). In
preliminary experiments, we found that labeled Ad5 virions reached
equilibrium in attachment to HeLa cells after 45 min at 4°C with an
MOI of 400 PFU per cell. For attachment studies, 3.5 × 105 cells were incubated for 1 h on ice with equal
amounts of 3H-labeled Ad OD particles equivalent to an MOI
of 400 PFU/cell for Ad5 in 100 µl of ice-cold adhesion buffer (DMEM
supplemented with 2 mM MgCl2, 1% bovine serum albumin, and
20 mM HEPES). Next, the cells were pelleted by centrifugation for 4 min
at 1,000 × g and washed two times with 0.5 ml of
ice-cold PBS. After the last wash, the cells were pelleted at
1,500 × g, the supernatant was removed, and the
cell-associated radioactivity was determined by a scintillation
counter. The number of viral particles bound per cell was calculated
using the virion-specific radioactivity and the number of cells. To
determine the fraction of internalized 3H-labeled Ad
particles, cells were incubated on ice for 1 h with the
corresponding virus, washed with PBS as described above, resuspended in
100 µl of adhesion buffer, and then incubated at 37°C for 30 min.
Following this incubation, cells were diluted threefold with cold
0.05% trypsin-0.5 mM EDTA solution and incubated at 37°C for an
additional 5 to 10 min. This treatment removed 99% of attached radioactivity. Finally, the cells were pelleted at 1,500 × g for 5 min, the supernatant was removed, and the
protease-resistant counts per minute were measured. This protocol
minimizes the possibility that the internalization data were affected
by receptor recycling (58). Nonspecific binding of Ad
particles to cells on ice was determined in the presence of 100-fold
excess of unlabeled virus. This value routinely represented less than
0.1% of viral load.
Flow cytometry.
Adherent cells (CHO and HeLa) grown in
non-tissue culture-treated 10-cm-diameter dishes (Falcon, Franklin
Lakes, N.J.) were detached by treatment with 1 mM EDTA and washed three
times with wash buffer (WB), consisting of PBS supplemented with 1%
FCS. Cells grown in suspension (K562 and CD34+) were washed
three times with WB. After washing, cells were resuspended in WB at
2 × 106 cells/ml; 2 × 105 cells
were incubated in WB for 1 h at 37°C with monoclonal antibodies (MAbs) specific for
v integrins (L230 [ATCC] or
HB-8448 [59]; 1/30 final dilution]), CAR (RmcB
[3, 26] [1/400 final dilution]), or
bromodeoxyuridine (BrdU; Amersham; 1/100 final dilution). Subsequently, cells were washed with WB and incubated with fluorescein isothiocyanate (FITC)-labeled horse anti-mouse immunoglobulin G (IgG) antibodies (Vector Laboratories, Burlingame, Calif.; 1/100, final dilution) or
phycoerythrin (PE)-labeled goat anti-mouse IgG antibodies (Calbiochem, La Jolla, Calif.; 1:100 dilution) for 30 min at 4°C. After incubation with secondary antibodies, cells were washed two times with WB and
104 cells per sample were analyzed in duplicate by flow cytometry.
For the analysis of CD34 and c-Kit expression on transduced
CD34
+ cells and for fluorescence-activated cell sorting
(FACS), purified
human CD34
+ cells were incubated with a
PE-conjugated anti-CD34 MAb (Becton
Dickinson Immunocytochemistry
Systems, San Jose, Calif.) or with
PE-labeled anti-CD117 (c-Kit) MAb
95C3 (Immunotech, Beckman Coulter,
Marseille, France) according to the
manufacturer's protocol, followed
by flow cytometry analysis. All
analyses and sortings were performed
on a FACStar Plus flow cytometer
(Becton Dickinson, Franklin Lakes,
N.J.) equipped with 488-nm argon and
633-nm HeNe lasers. For analysis
of c-Kit expression and FACS
purification of CD34
+ c-Kit
+ cells, SCF was not
added to the medium during culturing of CD34
+ cells.
Quantitative replication assay.
CD34+ or K562
cells (105) were infected in 100 µl of growth medium with
different MOIs of Ad5, Ad9, or Ad35 which had been amplified in 293 cells expressing the XhoI DNA methyltransferase isoschizomer PaeR7 (51). After 2 h of incubation at
37°C, the cells were centrifuged at 1,000 × g for 5 min, the virus-containing medium was removed, and the cells were
resuspended in 100 µl of fresh medium and then incubated at 37°C
until harvesting. At 16 h postinfection for K562 cells or 36 h postinfection for CD34+ cells, 5 µg of pBlueScript
(Stratagene, La Jolla, Calif.) plasmid DNA was added as a carrier which
could also be used as a loading control. Genomic DNA was extracted as
described previously (41). One-fourth of the purified
cellular DNA (equivalent to 2.5 × 104 cells) was
digested with HindIII, XhoI, or both
HindIII and XhoI at 37°C overnight and
subsequently separated in a 1% agarose gel followed by Southern blot
with chimeric Ad5/9 or Ad5/35 DNA probes. The chimeric probes,
containing sequences of Ad5 and Ad9 (Ad5/9) or Ad5 and Ad35 (Ad5/35),
were generated by a two-step PCR amplification using Pfu-Turbo DNA
polymerase (Stratagene) and viral DNA from purified particles as a
template. The following primers were used for PCR (Ad5 sequences and
nucleotide numbers are underlined): Ad5F1 (nucleotides [nt]
32775 to 32805), 5'-GCC CAA GAA TAA AGA ATC GTT TGT
GTT ATG-3'; Ad5R1 (nt 33651-33621), 5'-AGC TGG
TCT AGA ATG GTG GTG GAT GGC GCC A-3'; chimeric Ad5/9F (nt
31150 to 31177; nt 181 to 208), 5'-AAT GGG TTT CAA
GAG AGT CCC CCT GGA GTC CTG TCA CTC AAA CTA GCT GAC CCA-3';
chimeric Ad5/9R (nt 32805 to 32775; nt 1149 to 1113),
5'-CAT AAC ACA AAC GAT TCT TTA TTC TTG GGC TTC ATT CTT GGG
CGA TAT AGG AAA AGG-3'; chimeric Ad5/35F (nt 31150 to
31177; nt 132 to 159), 5'-AAT GGG TTT CAA GAG AGT CCCCCT
GGA GTT CTT ACT TTA AAA TGT TTA ACC CCA-3'; chimeric Ad5/35R (nt
32805 to 32775; nt 991 to 958), 5'-CAT AAC ACA AAC
GAT TCT TTA TTC TTG GGC ATT TTA GTT GTC GTC TTC TGT AAT GTA
AG-3'. Nucleotide numbers are given according to the sequences obtained
from the National Center for Biotechnology Information GenBank
(accession no. M73260/M29978 for Ad5, X74659 for Ad9, and U10272 for
Ad35). After the first amplification, the 968-bp-long Ad9, an
859-bp-long Ad35 DNA fragment corresponding to the fiber genes, and an
876-bp-long Ad5 fragment corresponding to the Ad5 E4 region (located
immediately downstream of Ad5 fiber gene) were purified by agarose gel
electrophoresis. To generate chimeric DNA probes, amplified Ad5 DNA was
mixed with Ad9 or Ad35 fragments obtained during the first step of PCR
and subjected to a second PCR amplification using Ad5/9F or Ad5/35F primers and the Ad5R1 primer. The resulting Ad5/9 or Ad5/35 chimeric DNA fragments (see Fig. 4C) were purified, and their concentrations were measured spectrophotometrically. Corresponding chimeric DNA fragments were loaded as concentration standards on agarose gels or
labeled with [32P]dCTP and used as probes for Southern
analysis. The number of viral genomes per DNA sample was calculated
after quantitative phosphorimager analysis. In preliminary experiments,
no preferential hybridization of chimeric DNA probes to DNA of any
particular viral serotype was detected.
Construction of chimeric Ad vectors.
For transduction
studies, we constructed two Ad vectors, Ad5GFP and Ad5GFP/F35,
containing a chimeric Ad5/35 fiber gene. Both Ad vectors contained a
2.3-kb, cytomegalovirus (CMV) promoter-driven enhanced green
fluorescent protein (EGFP) gene (derived from pEGFP-1 [Clontech,
Palo Alto, Calif.]) inserted into the E3 region of Ad5. The EGFP
expression cassette was cloned between Ad5 positions 25191 to 28191 and
30818 to 32507 into a shuttle plasmid, which contained the E3 deletion
described for pBHG10 (Microbix). The resulting plasmid was named
pAdGFP. For the chimeric vector, the Ad5 fiber gene in pAdGFP was
substituted by an Ad5/35 chimeric fiber gene generated by the two-step
PCR protocol outlined above. In the first PCR step, three DNA fragments
corresponding to (i) the Ad5 fiber 5' nontranslated region and the
first 132 bp of the fiber tail domain (nt 30798 to 31178), (ii) the
Ad35 shaft and knob domains (nt 132 to 991), and (iii) the Ad5 E4
region including the Ad5 fiber polyadenylation signal (nt 32775 to
33651) were amplified by Pfu-Turbo DNA polymerase. The following
primers were used: for the Ad5 tail, Ad5F-2 (nt 30798 to 30825; 5'-CGC GAT ATC GAT TGG ATC CAT TAA CTA-3') and Ad5R-2 (nt 31178 to 31153; 5'-CAG GGG GAC TCT CTT GAA ACC CAT T-3'); for the Ad35 shaft and knob,
primers Ad5/35F and Ad5/35R (see above); for the Ad5E4 and polyA,
primers Ad5F-1 and Ad5R-1 (see above). After 10 PCR cycles, the
products were purified by agarose gel electrophoresis, combined, and
then subjected to a second PCR with primers Ad5F-2 and Ad5R-1. The
resulting 2,115-bp-long chimeric fiber gene contained the Ad5 tail and
the Ad35 shaft and knob domains. This product was used as a substitute
for the SalI/XbaI Ad5 fiber gene containing fragment in pAdGFP. The resulting plasmid was named pAdGFP/F35. To
generate full-length E1/E3 vector genomes, pAdGFP and pAdGFP/F35 were
inserted in pAdHM4 (49) by recombination in
Escherichia coli (8). To do this, the
RecA+ E. coli strain BJ5183 was cotransformed
with pAdHM4 linearized by SrfI mixed with the
XbaI fragments containing the GFP genes, the Ad5 or Ad5/35
fiber genes, and the Ad5 homology regions. The resulting recombinants
were analyzed by restriction analysis. Correct recombinants were
amplified in E. coli HB101 and purified by double CsCl
gradient banding. The plasmids were named pAd5GFP and pAd5GFP/F35. The
correct structure of the Ad5/35 chimeric fiber gene was confirmed by
endonuclease digestion and sequencing part of pAd5GFP/F35. To produce
the corresponding viruses, pAd5GFP and pAd5GFP/F35 were digested with
PacI to release the viral genomes and transfected onto 293 cells as described elsewhere (41). Plaques developed 7 to 10 days posttransfection in overlaid cultures. Recombinant viruses were
propagated in 293 cells and purified by standard methods described
elsewhere (41).
Hemagglutination assay.
Twenty-five-microliter aliquots of
serial dilutions of Ad5, Ad35, or chimeric Ad5GFP/F35 virions in
McIlvaine-NaCl buffer (0.1 M citric acid-0.2 M
Na2HPO4 [pH 7.2], diluted 1:50 with 0.87% NaCl) were loaded onto 96-well plates. To each dilution, 25 µl of a
1% suspension of monkey erythrocytes (in McIlvaine-NaCl buffer) was
added. The sedimentation pattern was determined after incubation for
1 h at 37°C. All tests were performed in quadruplicate in at
least two independent experiments.
Southern blotting.
Extraction of genomic DNA, labeling of
DNA fragments, and hybridization were performed as described earlier
(41).
 |
RESULTS |
CAR and
v integrin expression on test cells.
It
is generally accepted that CD34+ cells possess bone
marrow-repopulating activity. Therefore, we used human
CD34+ cells as the target for our studies to identify Ad
serotypes with HSC tropism and constructing new viral vectors. Studies
were performed on mobilized, CD34-positive peripheral blood cells from one donor under conditions which are known to retain CD34+
cells in a quiescent stage (37, 57). More than 90% of
purified cells were CD34 positive by flow cytometry. Furthermore, we
included into our Ad tropism studies the cell line K562, which is
considered to be an adequate model for studying gene transfer into
human hematopoietic cells (44). HeLa cells, which are
readily infectible by Ad5, and CHO cells, which are refractory to Ad5
infection (3), were used as positive and negative control
cell lines, respectively.
For Ad5, both binding to the primary receptor and binding to
v
3 and
v
5
integrins are important for high-efficiency infection
of target cells.
The expression of CAR and
v integrins on test
cells was
analyzed by flow cytometry using MAbs against CAR (RmcB
[
3,
26]) and
v integrins (L230
[
59]) (Fig.
1). As
expected,
nearly all HeLa cells expressed high levels of CAR and
v integrins,
whereas CHO cells lacked significant CAR
and
v integrin expression.
Fifteen and 77% of K562
cells expressed CAR and
v integrins,
respectively. Only
~6% of the CD34
+ cells used in our studies
expressed CAR, and 17% were positive
for
v
integrins. Notably, the preparation of CD34
+ cells
represents a mixture of different cell types. The absent
or low
expression of primary and secondary Ad5 receptors on noncycling
human
CD34
+ cells is in agreement with previous reports (
27,
50,
73).

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 1.
Expression of CAR and v integrins on test
cells. For flow cytometry analysis, HeLa, CHO, K562, and
CD34+ cells were incubated with an anti-CAR (RmcB; 1:400
dilution) or anti- v integrin (L230; 1:30 dilution) MAb.
As a negative control, cells were incubated with an irrelevant mouse
MAb (anti-BrdU; 1:100 dilution). The binding of primary antibodies was
developed with anti-mouse IgG-FITC conjugates (1:100 dilution). Data
shown represent the average results of quadruplicate analyses performed
on 104 cells.
|
|
Serotype screening.
It is thought that different Ad serotypes
bind to different cellular receptor proteins and use different entry
mechanisms (15, 43). A set of human Ad serotypes was
obtained from the ATCC to be tested for tropism to CD34+
cells. These included serotypes 3, 4, 5, 9, 35, and 41 representing different subtypes (Table 1). We
hypothesized that these serotypes would use different cellular
attachment and internalization strategies due to differing lengths of
fiber shafts (11, 60), the presence or absence of RGD motifs
within the penton base, and differing tissue tropism. The relatively
little characterized Ad35 was selected because it was found in
immunocompromised hosts, particularly in bone marrow recipients
(17, 18, 65). The latter observations prompted us to
speculate that bone marrow cells may be among the natural reservoirs
for Ad35.
Little is known about the stability of particles from serotypes other
than Ad5. Since the intactness of viral particles was
crucial for
comparative interaction studies, virions from the
serotypes specified
above were analyzed by EM. EM studies of negative-contrast-stained
Ad
suspensions demonstrated that the percentage of defective particles
(loss of icosahedral shape or luminal staining) did not exceed
5%,
indicating that serotype preparations had comparable qualities.
Representative EM photographs are shown for Ad5, Ad9, and Ad35
(Fig.
2).

View larger version (80K):
[in this window]
[in a new window]
|
FIG. 2.
EM analysis of Ad particles. Purified particles from
Ad5, Ad9, and Ad35 were negative contrast stained and analyzed at an
original magnification of ×85,000. Defective particles are highlighted
by arrows.
|
|
To analyze attachment of Ad particles to target cells and subsequent
internalization, the selected serotypes were metabolically
labeled with [
3H]thymidine, which is incorporated
into viral DNA during replication.
Adsorption and internalization can
be experimentally dissociated
by taking advantage of the observation
that at low temperature
(0 to 4°C) only virus cell attachment occurs,
whereas internalization
requires incubation at higher temperatures. The
number of particles
adsorbed or internalized per cell was calculated
using the virion-specific
radioactivity and used to quantify
interaction of Ad serotypes
3, 4, 5, 9, 35, and 41 with
CD34
+, K562, HeLa, and CHO cells (Fig.
3). The serotypes varied significantly
in
the ability to attach to and to be internalized by the different
cell
lines. For Ad5, the degree of attachment to the cell lines
tested
correlated with the level of CAR expression. In CHO cells,
which were
previously shown to be refractory to Ad5 infection,
the level of
attachment and internalization was about 50 to 70
viral particles per
cell. This number was hereafter assumed negative
in terms of
susceptibility of a given cell type for Ad5. Interaction
of the other
serotypes with CHO cells was not significantly higher,
indicating that
corresponding receptors were absent on CHO cells.
All serotypes tested
interacted with HeLa cells, Ad3 and Ad35
being the most efficient
variants. The presence of distinct Ad3
and Ad5 receptors on HeLa cells
was demonstrated previously (
69).
Ad4, Ad5, and Ad41 did not
bind to K562 cells. In contrast, Ad9
as well as the members of subgroup
B, Ad3 and Ad35, efficiently
interacted with K562 cells, Ad35 having
the highest number of
adsorbed and internalized particles. About 25 times more Ad5 than
Ad35 particles were attached, and three-fourths of
these were
internalized by K562 cells. Viral interactions with
CD34
+ cells were generally weaker. Among the serotypes
tested, only
Ad9 and Ad35 were significantly internalized by noncycling
CD34
+ cells. Internalization of Ad9 and that of Ad35 were,
respectively,
four and eight times more efficient than for Ad5
particles. The
number of Ad35 virions internalized by CD34
+
cells was almost half of that seen for Ad5 in HeLa cells, which
can be
readily infected with Ad5-based vectors.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of attachment and internalization of different
serotypes to CHO, HeLa, K562, and CD34+ cells. Equal
amounts of [3H]thymidine-labeled virions of Ad serotypes
3, 4, 5, 9, 35, and 41 (measured by OD260 and equivalent to
an MOI of 400 PFU per cell for Ad5) were incubated for 1 h on ice
as described in Materials and Methods. Cells were then washed, and the
number of labeled virions bound per cell was determined. For
internalization studies, viruses were first allowed to attach to cells
for 1 h on ice, and then unbound viral particles were washed out.
Cells were then incubated at 37°C for 30 min, treated with
trypsin-EDTA, and washed to remove uninternalized viral particles. The
data were obtained from two to four independent experiments performed
in triplicate. Note the different scales on the y axes for
CD34+ cells.
|
|
In summary, of all serotypes tested, Ad9, Ad3, and Ad35 demonstrated
the most efficient attachment to and internalization
with K562 and
CD34
+ cells. Based on adsorption/internalization data, Ad9
and Ad35
as representatives for subgroups D and B were selected for
further
tropism
studies.
Replication of selected serotypes in K562 and CD34+
cells.
Adsorption/internalization studies do not ultimately prove
viral transduction, a process often defined as gene transfer that allows for viral or heterologous gene expression in host cells. Intracellular trafficking, including endosomal lysis, transport to the
nucleus, and nuclear import of the viral genome, depends on structural
capsid proteins and thus varies between different serotypes (15,
48). We hypothesized that analysis of viral gene expression would
be a means to verify successful nuclear import of viral genomes and
that this would be a good criterion for selection of serotypes able to
efficiently infect our target cells. To do this, we studied Ad DNA
replication in infected cells; viral DNA synthesis can occur only after
de novo expression of Ad early genes. We used a site-specific
methylation strategy to monitor viral DNA replication within infected
cells (51). Methylated Ad serotypes were produced by the
addition of a methyl group onto the N6 position of the adenine base of
XhoI sites, CTCGAG, during propagation of the
viruses in 293 cells expressing the XhoI isoschizomer PaeR7 methyltransferase (33). Loss of methylation
through viral replication restores XhoI cleavage and can be
detected by Southern blots of XhoI-digested genomic DNA from
infected cells.
Ad replication studies were performed in K562 and CD34
+
cells with Ad9 and Ad35, in comparison to Ad5. For replication studies,
the infectious titer (in PFU per milliliter) and genome titer
(in
genomes per milliliter) were determined (by plaque assay on
293 cells
and by quantitative Southern blot, respectively) for
methylated and
unmethylated Ad5, Ad9, and Ad35 (Table
2). The
ratio of PFU to genome titer was
comparable for methylated and
unmethylated virus, demonstrating that
DNA methylation had not
altered transduction properties (data not
shown). About 85% of
the Ad5, Ad9, and Ad35 used for infection was
methylated, as calculated
based on the intensity of fragments specific
for methylated and
nonmethylated viral DNA present in the viral load
(Fig.
4). The
numbers of genomes detected
after adsorption (1 h, 0°C) or internalization
(2 h, 37°C)
correlated well with studies shown in Fig.
3. Ad9
and Ad35 interacted
more efficiently than Ad5 with K562 and CD34
+ cells.
Dose-dependent replication studies in K562 and CD34
+ cells
were performed with the same genome numbers of Ad5, Ad9,
and Ad35 (Fig.
4). The replication rate was measured based on
the ratio of
methylated to demethylated viral DNA after infection
with different
MOIs (2,100, 420, and 105 genomes per cell). In
K562 cells, efficient
replication (100% conversion from methylated
to unmethylated DNA) was
detected for Ad9 at MOIs of

420 and
for Ad35 at MOIs of

105. The
signal from internalized Ad5 genomes
was relatively weak,
reflecting the low level of Ad5 interaction
with K562 cells. This
complicated the analysis of Ad5 replication.
Clearly detectable
replication of Ad5 was observed only at MOIs
of

2,100 genomes per
cell. Taken together, these findings demonstrated
that Ad35 transduced
K562 cells with the highest efficiency. In
CD34
+ cells, the
replication rates were 100% for Ad5 and 31% for Ad9
after infection
with an MOI of 420. Although methylated Ad35 viral
DNA was present in
CD34
+ cells, viral replication was undetectable for Ad35.
In summary,
while viral replication studies in K562 cells confirmed
data obtained
for Ad5, Ad9, and Ad35 adsorption and internalization,
there was
a discrepancy between earlier results and the poor
replication
of Ad9 and, particularly, Ad35 in CD34
+ cells.
As outlined later, replication analysis in heterogeneous
cell
populations, like CD34
+ cells, may not allow for
definitive conclusions on tropism of
a particular serotype.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of viral replication in K562 and
CD34+ cells by Southern blot analysis of methylated viral
DNA. Replication studies were performed with 105 K562 (A)
or CD34+ (B) cells infected with methylated Ad5, Ad9, or
Ad35. The lanes labeled "load" represent DNA that was extracted
from the medium-cell mixture immediately after adding the indicated
viral dose to cells. The intensities of bands corresponding to
methylated and unmethylated viral DNA indicate that ~85% of the
input virus was methylated. To quantify adsorption and internalization,
DNA analysis was performed after prior incubation of virus with cells
at 0°C (adsorption) or 37°C (internalization). For dose-dependent
replication studies, the indicated viral dose (expressed as the number
of genomes per cell) was added, and cellular genomic DNA together with
viral DNA was extracted 16 or 36 h postinfection for K562 and
CD34+ cells, respectively. Identical amounts of sample DNA
were analyzed by Southern blotting. For quantification purposes, Ad9
replication was analyzed together with Ad5, using an Ad5/9 chimeric
probe that hybridizes with DNA of both serotypes (C). The analysis of
Ad5 versus Ad35 replication was performed with the corresponding Ad5/35
chimeric probe. Since separate hybridizations with both Ad5/35 and
Ad5/9 probes gave identical signal intensities for Ad5 DNA, only one
panel is shown for Ad5 replication in test cells. To produce
distinguishable fragments specific for the methylated or nonmethylated
status of viral genomes, Ad5 DNA was digested with XhoI,
while Ad9 and Ad35 DNA was digested with XhoI and
HindIII. The bands specific for methylated (not
replicated) viral DNA were ~12 kb for Ad9, 35 kb for Ad5, and ~12
kb for Ad35. The fragments specific for nonmethylated DNA were 5.8 kb
for Ad9, 6.1 kb for Ad5, and 9.5 kb for Ad35. Chimeric Ad5/9 and Ad5/35
DNA fragments (1.8 kb) were used as quantification standards and
applied onto gels together with digested viral or cellular DNA (shown
on the left). Hybridized blots were subjected to quantitative
phosphorimager analysis or exposed to X-ray films for 12 h. Lanes
representing Ad5 replication data for K562 cells were also exposed for
48 h (A, left panel).
|
|
Taking all the screening data together, Ad9 and Ad35
emerged as the variants with the strongest tropism for K562 and
CD34
+ cells. It is thought that Ad9 can bind to CAR;
however, it preferentially
uses
v integrins for cell
entry (
59). This entry strategy may
not be optimal for
efficient infection of CD34
+ cells, as only less than 17%
of them express
v integrins (Fig.
1). Therefore, we
decided to concentrate on Ad35 as a source for
heterologous fiber to be
used for construction of a chimeric vector
based on an Ad5
backbone.
Construction and characterization of chimeric fiber.
Previously, it was shown that exchanging the fiber knob was sufficient
to alter the tropism of chimeric Ad vectors (10, 31, 70). As
outlined above, the length of the fiber shaft may critically determine
the entry strategy of a particular serotype. Therefore, we decided to
replace not only the Ad5 fiber knob but also the shaft. The chimeric
Ad5/35 fiber contained the Ad5 tail (amino acids 1 to 44) necessary for
interaction with the Ad5 penton base linked to 279 amino acids from
Ad35 including the shaft with seven
sheets and the knob (Fig.
5A). The endogenous Ad5 fiber poly(A)
signal was used to terminate transcription of the chimeric fiber gene.
The combination of the Ad5 capsid including the RGD motif containing
penton base with a short-shafted fiber could be risky because the
natural distance between the fiber knob and the RGD motifs was
disturbed. Nevertheless, the Ad5 fiber was replaced by the chimeric
fiber sequences based on an E1/E3-deleted Ad vector. This vector
carried a CMV promoter-GFP reporter gene cassette inserted into the E3
region. The corresponding chimeric virus (Ad5GFP/F35) was produced in
293 cells at a titer of >2 × 1012 genomes per ml.
For comparison, an E1/E3-deleted Ad vector containing the original Ad5
fiber gene and the GFP expression cassette was generated (Ad5GFP). The
titer and the ratio of physical to infectious particles were similar
between Ad5GFP and Ad5GFP/F35, indicating that the fiber modification
did not significantly alter the stability and/or growth properties of
the chimeric vector (data not shown). The correctness of the fiber
modification was confirmed by restriction analysis of the Ad5GFP/F35
viral genome followed by Southern blot hybridization (Fig. 5B), direct
sequencing of the fiber-coding region, and a functional test for
hemagglutination of monkey erythrocytes. The agglutination of
erythrocytes is fiber knob mediated; it is known that Ad5 does not
agglutinate monkey erythrocytes, whereas Ad35 efficiently does
(55). In hemagglutination tests, Ad5GFP/F35 agglutinated
monkey erythrocytes with the same efficiency as Ad35 at dilutions of up
to 1:512. In contrast, no hemagglutination was observed with equivalent
Ad5 dilutions. This clearly confirmed the functional activity of the
chimeric Ad5/35 fiber incorporated into Ad5 capsid.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 5.
Structure of Ad5GFP and chimeric Ad5GFP/F35
vectors. (A) Schematic diagram of the original E1/E3-deleted Ad5-based
vector with GFP expression cassette inserted into the E3 region
(Ad5GFP) and the chimeric vector Ad5GFP/F35 containing the Ad5/35 fiber
gene. The 2.2-kb Ad5 fiber gene was replaced by a 0.9-kb chimeric fiber
gene encoding the short shaft and knob of Ad35 by a technique that
involved PCR cloning and recombination in E. coli.
KpnI (K) and HindIII (H) sites localized
within or around the fiber genes are indicated. The lower panel shows
the detailed structure of the chimeric fiber region. The Ad5 fiber tail
(amino acids [aa] 1 to 44) were joined in frame to the Ad35 fiber
shaft starting from its first two amino acids (GV), which are conserved
among many serotypes. A conserved stretch of amino acids, TLWT, marks
the boundary between the last sheet of Ad35 shaft and the globular
knob. The Ad35 fiber chain termination codon is followed by the Ad5
fiber polyadenylation signal. The region of Ad5GFP/F35 encoding for
chimeric fiber was completely sequenced with Ad5-specific primers (see
Materials and Methods). ITR, inverted terminal repeat; bPA, bovine
growth hormone polyadenylation signal. (B) Restriction analysis of
viral genomes. Viral DNA was isolated from purified Ad5GFP and
Ad5GFP/F35 particles as described elsewhere (41). One
microgram of DNA was digested with HindIII or
KpnI and separated in ethidium bromide-stained agarose gels
(left) which were subsequently blotted and analyzed by Southern blot
with an Ad5 E4-specific probe (nt 32775 to 33651) (right). Specific
patterns designating the correct structure for both viral vectors
were detected. The HindIII fragments specific for Ad5GFP
and Ad5GFP/F35 were 2.9 and 4.9 kb, respectively. The KpnI
fragment that confirmed the correct Ad5GFP/F35 structure was 1.6 kb,
compared to a 7.6-kb Ad5GFP fragment. M, 1-kb ladder (Gibco-BRL, Grand
Island, N.Y.).
|
|
Competition studies.
Cross-competition studies between Ad5,
Ad35, and Ad5GFP/F35 for binding and internalization were performed to
investigate in more detail the pathways used by the chimeric vector to
infect target cells. Wild-type Ad35 and the chimeric vector Ad5GFP/F35 could recognize the same primary receptor, as they competed with each
other for attachment to K562 cells (Fig.
6A, upper panel). This primary receptor
is different from that used by Ad5, since neither Ad5 viral particles
nor anti-CAR MAbs (Fig. 6B, upper panel) were able to abrogate Ad35 or
Ad5GFP/F35 binding. In competition studies for internalization, Ad35
and Ad5GFP/F35 competed with each other with equal efficiency. Ad5 and
anti-
v integrin MAb L230 (Fig. 6, lower panels) did not
inhibit internalization of Ad35 or the chimeric virus. To consolidate
these data, K562 cells were infected with Ad5GFP and
Ad5GFP/F35 after prior incubation of cells with anti-CAR or
anti-
v integrin MAbs followed by analysis of
GFP-expressing cells. The transduction data mirror the results obtained
in adsorption/internalization studies (data not shown). In summary,
this demonstrated that Ad35 and Ad5GFP/F35 use a CAR- and
v integrin-independent pathway for infection of K562
cells; the structural elements which account for these specific
properties are located within the Ad35 fiber and can be transplanted
into Ad5 by fiber substitution.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 6.
Cross-competition for attachment and
internalization of labeled Ad5GFP, Ad35, and chimeric Ad5GFP/F35
virions with unlabeled viruses and with anti-CAR or
anti- v integrin MAb. (A) For attachment studies,
105 K562 cells were preincubated with a 100-fold excess of
unlabeled competitor virus (cold competitors) at 4°C for 1 h;
then equal amounts of [3H]Ad5GFP,
[3H]Ad5GFP/F35, or [3H]Ad35, at a dose
equivalent to an MOI of 100 PFU per cell determined for Ad5GFP, were
added to cells, which were incubated at 4°C for 1 h. Cells were
then washed with ice-cold PBS and pelleted, and the percentage of
attached virus (cell-associated counts per minute) was determined. For
analysis of cross-competition for internalization, cells were
preincubated with a 100-fold excess of competitor virus at 37°C for
30 min before labeled virus was added. After an additional incubation
at 37°C for 30 min, cells were treated with trypsin-EDTA for 5 min at
37°C, washed with ice-cold PBS, and pelleted, and the percentage of
internalized virus was determined. For controls, cells were incubated
with labeled viruses without any competitors. Preliminary experiments
had shown that the conditions chosen for competition studies allowed
for saturation in attachment or internalization on K562 cells for all
unlabeled competitors. As a control, 3H-labeled viruses
were incubated with cells without any competitor. (B) K562 cells
(105) were preincubated for 1 h at 4°C with an
anti-CAR (RmcB; diluted 1:100) or anti- v integrin (L230;
diluted 1:30) MAb and then incubated with labeled viruses according to
the protocols for attachment or for internalization as described above.
For each particular serotype, the percentage of attached or
internalized virus was compared to the control settings, where cells
were preincubated under the same conditions with a 1:100 dilution of an
irrelevant antibody (anti-BrdU MAb) before addition of the labeled
virus. Note that the specific competitors but not the corresponding
controls significantly inhibited Ad5 internalization to a degree that
is in agreement with published data (59). n 4.
|
|
We demonstrated earlier that Ad3 can efficiently interact with
K562 cells (Fig.
3). Although Ad3 and Ad35 belong to the same
subgroup
(B), the homology between amino acid sequences of their
fibers is only
about 60%. Therefore, we decided to test whether
Ad3 could compete
with Ad35 and Ad5GFP/F35 for attachment and
internalization (Fig.
7). These studies demonstrated that
Ad35
binding was not inhibited by Ad3, indicating the use of different
receptors. Interestingly, Ad3 slightly inhibited attachment of
Ad5GFP/F35 (Fig.
7A, left panel). We speculate that in addition
to
binding to the receptor common for the Ad35 and Ad5GFP/F35
fiber, the
chimeric capsid (e.g., the Ad5 penton RGD motifs) also
interacts with a
second cellular receptor that overlaps with elements
involved in Ad3
binding. In cross-competition for internalization,
preincubation of
cells at 37°C with Ad35 and with chimeric virus
significantly
decreased internalization of
3H-labeled Ad3 (Fig. B, right
panel). In the reverse experiment,
Ad3 as competitor decreased the
level of internalization by 30%
for both Ad35 and the chimeric virus
(Fig.
7A, right panel). As
expected, Ad5 and Ad3 did not compete
for adsorption or internalization.
As shown before (Fig.
6B), anti-CAR
and anti-
v integrin antibodies
did not block Ad3
interaction with K562 cells. In summary, we
concluded that Ad35 and
Ad5GFP/F35 bind to a receptor(s) different
from that of Ad3.
However, Ad35, Ad5GFP/F35, and Ad3 appear to
use common
structural elements for internalization, which are
different from
v integrins.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 7.
Cross-competition for attachment and internalization of
Ad5GFP, Ad35, and Ad5GFP/F35 with Ad3. (A) K562 cells (105)
were preincubated with a 100-fold excess of unlabeled Ad3 according to
attachment or internalization protocols described for Fig. 6. Equal
amounts of [3H]Ad5GFP, [3H]Ad5GFP/F35,
[3H]Ad35, or [3H]Ad3 were added to cells at
a dose equivalent to an MOI of 100 PFU per cell for Ad5GFP. Control
settings represent attachment or internalization of
[3H]Ad3 without competitor. (B) 3H-labeled
Ad3 was incubated with a 100-fold excess of cold (unlabeled) virus
(Ad5GFP, Ad5GFP/F35, Ad35, or Ad3). In control settings, cells were
incubated with labeled viruses without any competitors. n = 4.
|
|
Infection studies with chimeric virus.
So far, we have
established that Ad5GFP/F35 infected K562 cells by a CAR- and
v integrin-independent pathway. We hypothesized that
this property may allow for efficient transduction of noncycling CD34+ cells, which express scarcely CAR and
v integrins. To test this, the transduction properties
of Ad5GFP and Ad5GFP/F35 vectors were analyzed on CD34+,
K562, and HeLa cells. Figure 8 shows the
percentage of transduced, GFP-expressing cells depending on the MOI
used for infection. Nearly 100% of HeLa cells were transduced with
Ad5GFP and Ad5GFP/F35 at MOIs of
25. More than 95% of the K562 cells
were transduced with Ad5GFP/F35 at MOIs of
100, whereas the
transduction rate was significantly lower with Ad5, in which case it
increased, with the MOI reaching a plateau at ~70% GFP-positive
cells after infection with an MOI of 400. Transduction of
CD34+ cells was about threefold more efficient with
Ad5GFP/F35 than with Ad5GFP at all MOIs analyzed. Interestingly, at
higher MOIs, the transduction rate did not rise proportionally with the
viral dose and soon reached a plateau, indicating that in both cases only specific subsets of CD34+ cells were permissive to
infection.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 8.
Transduction of CD34+, K562, and HeLa cells
with Ad5GFP and chimeric Ad5GFP/F35 vectors. Cells (105)
were infected with different MOIs (PFU per cell) of viruses in 100 µl
of medium for 6 h at 37°C. Virus-containing medium was then
removed, and the cells were resuspended in fresh medium followed by
incubation for 18 h at 37°C. The percentage of GFP-expressing
cells was determined by flow cytometry. n = 3.
|
|
To characterize in more detail these specific, permissive subsets,
additional transduction studies were performed. First,
the percentage
of GFP-expressing cells was determined in CD34
+ fractions
that were stained for
v integrins or CARs (Fig.
9).
The low number of CAR-positive
CD34
+ cells complicated accurate colabeling studies;
however, it appears
that there was no correlation between CAR
expression and the proportion
of transduced cells among
CD34
+ cells infected with Ad5GFP or Ad5GFP/F35.
Interestingly, for
Ad5GFP, 65% of all GFP-expressing cells were
positive for
v integrins,
whereas less than 22%
of GFP-positive cells infected with the
chimeric virus stained
positive for
v integrin expression. While
only
17% of the whole CD34
+ population expressed GFP after
Ad5GFP infection, the percentage
of GFP-expressing cells in the
CD34
+
v integrin-positive fraction was 50%.
This indicates that Ad5GFP
vector-mediated GFP expression was
preferentially localized to
v integrin-positive
CD34
+ subsets, whereas after infection with the
Ad5GFP/F35 vector,
GFP was expressed in a broader spectrum of
CD34
+ cells, most of them being
v integrin
negative. It remains to
be determined whether there is a
correlation between
v integrin
expression and the
differentiation status of CD34
+ cells.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 9.
Distribution of GFP-positive cells in subpopulations of
human CD34+ cells expressing CAR or v
integrins. CD34+ cells (105) were infected with
Ad5GFP or Ad5GFP/F35 at an MOI of 200 PFU/cell as described for Fig. 8.
Twenty-four hours after infection, cells were incubated with anti-CAR
(1:100 final dilution) or anti- v integrin (1:30 final
dilution) primary MAb for 1 h at 37°C. Binding of primary
antibodies was developed with anti-mouse IgG-PE secondary MAbs (1:100
final dilution) at 4°C for 30 min. For each variant, 104
cells were analyzed by flow cytometry. The mock infection variants
represent cells incubated with virus dilution buffer only. The quadrant
borders were set based on the background signals obtained with both the
GFP- and PE-matched negative controls. The percentages of stained cells
found in each quadrant are indicated. The data shown are representative
of three independent experiments.
|
|
Next, transduced cells were simultaneously analyzed for GFP
as well as for CD34 and CD117 markers. As mentioned before, only
about 90% of all cells used in our analysis were positive for
CD34 at
the time of infection, hence the multiparameter analysis
for CD34 and
GFP. A population of CD34
+ cells is extraordinarily
heterogeneous in morphology and stem
cell capacity. The subpopulation
of CD34
+ and CD117
+ cells resembles very
primitive hematopoietic cells (
29,
67).
Figure
10 summarizes the
analyses of GFP expression in correlation
with these specific
stem cell markers. A total of 92%, 89 (66
+ 23)%, or 92 (42 + 50)% of all analyzed cells were CD34 positive
in the
mock-infected, Ad5GFP-infected, or Ad5/35GFP-infected
samples,
respectively (Fig.
10A, lower panel). From these
CD34-positive
cells, 54% (50 out of 92) were also positive
for GFP after infection
with the Ad5GFP/F35 chimeric vector, whereas
only 25% (23 out
of 89) of all CD34-positive cells expressed GFP after
infection
with the Ad5 vector. Analogously, the percentage of
GFP-expressing
cells among all CD117-positive cells was
calculated. From all
CD117-positive cells, 80% (20 out of 25)
were also positive for
GFP after infection with the Ad5GFP/F35
chimeric vector, whereas
only 36% (8 out of 22) of all CD117-positive
cells expressed GFP
after infection with the Ad5 vector (Fig.
10A,
middle panel). In
an additional experiment, CD34
+ cells
were sorted for CD117 expression prior to infection with
Ad5GFP or
Ad5GFP/F35; 24 h postinfection, GFP expression was analyzed
in
this specific fraction (Fig.
10B). This analysis revealed that
the
chimeric vectors transduced fourfold more CD34
+
CD117
+ cells than the Ad5GFP vector.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 10.
Distribution of GFP-positive cells in a subpopulation
of human CD34+ cells expressing CD34 and CD117 (c-Kit). (A)
Colocalization of GFP expression with CD34 or CD117. CD34+
cells were infected with Ad5GFP or Ad5GFP/F35 at an MOI of 200 PFU/cell
under the conditions described for Fig. 8. Twenty-four hours after
infection, cells were incubated with anti-CD34 PE-conjugated MAbs
(final dilution, 1:2) or with anti-CD117 PE-conjugated MAbs (final
dilution, 1:5) for 30 min on ice, and 104 cells per variant were
subjected to two-color flow cytometry analysis. For negative control
staining, no antibodies were added to the cells before analysis. The
mock infection variants represent cells incubated with virus dilution
buffer only. The quadrant borders were set based on the background
signals obtained with both the GFP- and PE-matched negative controls.
The percentages of stained cells found in each quadrant are indicated.
The experiment was performed two times in triplicate, and typically
obtained results are shown. The standard error of the mean was less
than 10% of the statistical average. (B) Transduction of
CD34+ CD117+ cells with Ad5GFP and chimeric
Ad5GFP/F35 virus vectors. CD34+ cells, cultured overnight
before staining in media without SCF, were incubated with PE-labeled
anti-CD117 MAb for 30 min on ice. The fraction of CD117-positive cells
was sorted by FACS. More than 97% of sorted cells were positive for
CD117. CD117+ CD34+ cells (105)
were infected with Ad5GFP or Ad5GFP/F35 at an MOI of 200 PFU/cell as
for Fig. 8. Twenty-four hours postinfection, the percentage of
GFP-positive cells was determined by flow cytometry. For mock
infection, CD117+ CD34+ cells were incubated
with virus dilution buffer only. The infections were done in
triplicate, and the average percentage of GFP-expressing cells is
indicated on the corresponding histogram. The standard error of the
mean was less than 10% of the statistical average.
|
|
In conclusion, these results demonstrated that the chimeric Ad5GFP/F35
vector was clearly superior to the Ad5GFP vector in
targeting and
transduction of CD34
+ cells. Furthermore, the data suggest
that the spectrum of CD34
+ cell subsets permissive for Ad
infection was significantly different
for the chimeric vector than for
the Ad5
vector.
Analysis of viral genomes within CD34+ cells infected
with the Ad5 and chimeric vectors.
So far, the transduction rate
of CD34+ cells was measured based on GFP expression after
infection with Ad5GFP and Ad5GFP/F35. Considering the extraordinary
heterogeneity of CD34+ cells in morphological and
functional parameters, GFP may not be expressed in all cell types that
were efficiently infected; reasons for this include that the CMV
promoter is not active in all cell types or that the regulation of
transgene expression differs between subsets on a posttranscriptional
or posttranslational level. To test this, we quantified the number of
intracellular (transduced) viral genomes within GFP-positive and
GFP-negative fractions of CD34+ cells infected with Ad5GFP
and Ad5GFP/F35. To do this, 24 h after infection,
CD34+ cells were sorted for GFP-positive and GFP-negative
fractions, which were subsequently used to isolate genomic DNA together
with transduced viral DNA. The number of viral genomes was determined by quantitative Southern blot as described for Fig. 4. Per GFP-positive CD34+ cell, about 270 copies of the Ad5GFP/F35 viral genome
were detected. Interestingly, a remarkable 200 copies of the Ad5GFP/F35
viral genome were found per GFP-negative CD34+ cell (Fig.
11A). This demonstrated that not all
infected cells expressed GFP and implies that the actual transduction
rate was higher than 54% (GFP-positive cells). We speculated that the
CMV promoter was not active in all transduced CD34+
subsets. No Ad5GFP vector-specific signal was detected within infected
CD34+ (GFP-positive or -negative) fractions by Southern
blotting which had a detection limit of 14 viral genomes per cell. From
this, we can conclude that the vector DNA concentration per transduced cell was at least 20 times higher for Ad5GFP/F35 than for Ad5GFP.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 11.
Southern analysis of viral genomes in GFP-positive and
GFP-negative fractions of CD34+ cells infected with the
Ad5GFP and chimeric Ad5GFP/F35 vectors. CD34+ cells were
infected with viruses at an MOI of 100 as described for Fig. 8.
Twenty-four hours postinfection, cells were sorted by FACS for
GFP-positive and GFP-negative fractions; 105 cells from
each fraction were used to isolate genomic DNA together with viral DNA.
Before cell lysis, a rigorous treatment with trypsin and DNase followed
by washing was performed to exclude that genomic DNA samples were
contaminated by extracellular viral DNA. (A) The upper panel shows the
ethidium bromide-stained 1% agarose gel before blotting, demonstrating
that similar amounts of genomic DNA were loaded. This amount
corresponded to DNA isolated from ~25,000 GFP+ or
GFP cells. The lane labeled "Load" represents viral
DNA purified from Ad5GFP or Ad5GFP/F35 virions mixed with pBluescript
plasmid DNA (Stratagene) as a carrier and applied on a gel at the
amount that was actually used to infect 25,000 cells. As a
concentration standard, a serial dilution of Ad5GFP genomes was loaded
on the gel (left). For Southern analysis (lower panel), an 8-kb-long
HindIII fragment corresponding to the E2 region of Ad5
was used as a labeled probe. Hybridized filters were subjected to
phosphorimager analysis and then exposed to Kodak X-Omat film for
48 h at 70°C. The cellular/viral genomic DNA is indicated by
an arrow. (B) To detect Ad5GFP genomes in transduced cells, PCR
amplification followed by Southern blot hybridization was performed on
the same samples as used for quantitative Southern blot hybridization
in panel A. DNA purified from ~2,500 cells was subjected to PCR
(95°C for 1 min, 53°C for 1 min, 72°C for 1 min; 20 cycles with
primers Ad5-F1 and Ad5-R1). One-fifth of the PCR product was subjected
to agarose gel electrophoresis (upper panel). A 0.9-kb-long DNA
fragment specific to the E4 region of Ad5 was detected for transduced
Ad5GFP/F35 genomes. DNA then was blotted onto Nybond-N+ membrane, and
Southern blot hybridization (lower panel) with an Ad5 E4-specific DNA
probe was performed. In addition to the 0.9-kb DNA fragment, the PCR
primers generated a smaller 0.5-kb-long fragment that also hybridized
with the E4 region probe.
|
|
Ad5GFP DNA was detectable in DNA samples from infected
CD34
+ cells by Southern blotting only after prior PCR
amplification
with vector-specific primers (Fig.
11B). This indicates
that the
replication deficient Ad5 vector is present but at a very low
copy number, which may be limited by intracellular genome stability.
Using the PCR-Southern detection method, Ad5 vector DNA was also
detected in GFP-negative cells, supporting our hypothesis that
the CMV
promoter may not have been the optimal choice for transduction
studies.
It is notable that studies by others on viral genome
analyses after
infection of CD34
+ cells with Ad5 vectors were performed
only after prior PCR amplification
(
46,
50).
 |
DISCUSSION |
Our long-term goal is the development of viral vectors for stable
gene transfer into human HSCs. Towards this end, we tested the
interaction of selected Ad serotypes with CD34+ cells. As a
result of this screening, we constructed a first-generation, Ad5-based
vector whose fiber was substituted with the fiber derived from Ad35. We
demonstrated that this capsid modification allowed for efficient viral
transduction of potential HSCs by the corresponding chimeric Ad vectors.
All tropism and transduction studies were performed with noncycling
CD34+ cells, which are thought to include HSCs. The
quiescent stage of CD34+ cells purified from mobilized
blood is important because induction of cell proliferation is
associated with a loss of the ability to reconstitute hematopoiesis and
with changes in the spectrum of cellular receptors (2, 22,
28).
Although it was reported earlier that fiber knobs derived from Ad
serotypes 2, 9, 4, and 41L can bind to CAR in slot blot assays
(60), it is not clear whether this binding occurs with an
affinity that is physiologically relevant and whether this would confer
virus infection. Furthermore, as shown for the Ad5 interaction between
the penton and integrins, a secondary receptor is required to induce
virus internalization. We demonstrated that different serotypes
interacted differently with the K562 or CD34+ target cells.
Ad5, Ad4, and Ad41 were not able to efficiently attach to and be
internalized by K562 and CD34+ cells. Although Ad4 belongs
to a separate subgroup (E), it is thought that Ad4 represents a natural
hybrid between subgroup B and C viruses with a fiber related to Ad5
(23). Therefore, it was not surprising that Ad4 has binding
properties similar to those of Ad5. The subgroup F serotype Ad41 has
been shown to contain distinct fibers, a long-shafted and a
short-shafted fiber allowing for different cell entry pathways
(71). The Ad41 penton base does not contain RGD motifs,
suggesting that this virus may use
v
integrin-independent pathways for cell entry. However, these features
did not improve interaction with CD34+ cells. Ad9, Ad3, and
Ad35 did interact with CD34+ cells more efficiently than
Ad5. Out of all the serotypes tested, Ad35 demonstrated the most
efficient attachment and internalization with K562 and
CD34+ cells. Although the short-shafted Ad9 can bind to
CAR, it preferentially uses
v integrins for cell entry
(59). Therefore, the low level of
v integrin
expression on certain subsets of CD34+ cells may account
for the observed susceptibility to Ad9.
Viral replication studies in K562 cells confirmed the data obtained for
Ad5, Ad9, and Ad35 adsorption and internalization. However, there was a
discrepancy between the interaction data and the replication data for
CD34+ cells, where Ad9 replicated only poorly and no
replication was seen for Ad35. Ad DNA replication is initiated only
upon the production of a critical threshold of early viral proteins,
which in turn is directly dependent on the number of viral genomes
present in the nuclei of infected cells. Therefore, the outcome of
replication studies may be affected by the rate of nuclear import of
viral genomes, by the activity of viral promoters, and/or by the
intracellular stability of viral DNA or RNA. These parameters may vary,
on one hand, between different subsets of CD34+ and/or, on
the other hand, between different Ad serotypes. This implies that viral
replication analyses performed with different Ad serotypes in
CD34+ cells may not predict the actual transduction
properties of chimeric vectors based on Ad5 backbones.
Recently, an Ad serotype screening strategy was used to identify
variants with tropism for primary fetal rat central nervous system
cortex cells or human umbilical vein endothelial cells. The optimal
serotype (Ad17) was selected based on immunohistochemistry for hexon
production 48 h after infection (10). However, this approach is problematic because, at least in our hands, antibodies developed against Ad5 hexon did not efficiently cross-react with all
other serotypes. Also, hexon is expressed only after onset of
replication. As outlined above, the kinetics of intracellular trafficking, viral gene expression, and replication significantly vary
between serotypes (15, 48).
In addition to being the most efficient serotype in terms of
interaction with CD34+ cells, Ad35 is also interesting
because it interacts with receptors different from those with which Ad5
interacts. Ad35 and Ad5GFP/F35 attachment was not inhibited by Ad5 or
anti-CAR antibodies, suggesting that Ad35 binding was CAR independent.
Furthermore, our data indicate that infection with Ad35 and the
chimeric Ad5GFP/F35 vector does not involve
v integrins.
First, Ad5 did not compete with Ad35 and Ad5GFP/F35 in internalization
or infection studies, indicating that
v
3/5 integrins may not be involved in
viral entry. Second, function-blocking antibodies against
v integrins did not compete with Ad35 and Ad5GFP/F35 for
internalization into K562 cells, whereas these antibodies did inhibit
Ad5 internalization. Third, in contrast to Ad5-based vectors, GFP
expression after infection with Ad5GFP/F35 was not restricted to
v integrin-expressing CD34+ cells. In this
context, the presence or absence of RGD motifs within Ad35 penton base
remains to be determined by sequencing the corresponding genome region.
Cross-competition assays demonstrated that Ad35 and Ad5GFP/F35 bind to
a receptor that is different from the Ad3 receptor. Although Ad3 and
Ad35 belong to the same subgroup, they have been divided into two DNA
homology clusters, B1 and B2; the amino acids composing their fibers
are only 60% homologous. Furthermore, the target tissues for the two
viruses are different; Ad3 can cause acute respiratory infections,
whereas Ad35 is associated with kidney infections (25).
Therefore, it was not surprising to find that Ad3 and Ad35 recognize
different receptors.
In conclusion, Ad35 and the chimeric vector enter the cells by a CAR-
and
v integrin-independent pathway. We speculate that Ad35 and the chimeric vector binds primarily to its fiber receptor. This interaction may be sufficient to trigger internalization. On the
other hand, Ad35 internalization may involve cellular proteins which
appear to overlap with those for Ad3 internalization and may represent
2 integrins, which protrude more from the cell surface
than
v integrins (27).
Fiber substitution was sufficient to swap cell tropism from Ad5 to
Ad35. The Ad5GFP/F35 capsid chimera contained the short-shafted Ad35
fiber incorporated into an Ad5 capsid, instead of the naturally occurring long-shafted Ad5 fiber. The length of fiber shaft and the
precise spatial arrangement of knob and RGD motifs appear to be
critical for the viral entry strategies. So far, most of the chimeric
viruses have been generated by substituting only the Ad5 knob while
maintaining the long Ad5 fiber shaft (10, 32, 69, 70). The
exception was an Ad5/7 chimeric virus (20), where the whole
Ad5 fiber was substituted by the short-shafted Ad7 fiber. However,
similar to the parental Ad5, the Ad5/7 chimera still required
v integrins for infection. Importantly, the Ad5/35 capsid chimera allows for efficient infection of K652 and
CD34+ cells, suggesting that the protruding RGD motives in
the Ad5 penton base do not affect the interaction with the primary Ad35 receptor. We hypothesize that despite the presence of RGD motifs within
the Ad5 penton, the chimeric virus uses cell entry pathways determined
primarily by the receptor specificity of the short-shafted heterologous fiber.
Our data suggest that infection with Ad5-based vectors is restricted to
a specific subset of CD34+ cells. The percentage of
GFP-expressing cells after Ad5GFP infection of CD34+ cells
reached a plateau at MOIs higher than 100, indicating that only a
limited fraction of CD34+ cells was permissive to Ad5.
Also, strong replication of wild-type Ad5 in infected CD34+
cells may be the result of preferential transduction of a specific subpopulation of CD34+, resulting in an expression of early
viral genes at a level sufficient to initiate viral replication. The
presence of a specific subpopulation of CD34+ cells
permissive to Ad5 vector infection was suggested by others (6, 50). In the present report, we further
characterized this subpopulation and demonstrated that Ad5-based
vectors preferentially infected
v integrin-positive
CD34+ cells. Integrins (including
v) are
thought to be important for homing and trafficking of transplanted
hematopoietic cells; however, little is known about the correlation
between
v integrin expression and the differentiation
status of hematopoietic cells (54, 61). Importantly,
infection with the chimeric Ad5GFP/F35 vector was not restricted to the
v-positive CD34+ subpopulation.
Among CD34+ cells, the subpopulation of
CD34+ and CD117+ cells resembles very
primitive hematopoietic cells (29, 67). The receptor for
stem cell factor, CD117 (c-Kit), belongs to a tyrosine kinase family.
It was previously shown that c-Kit+ CD34+
cord blood cells contain a high fraction (16%) of hematopoietic progenitors (52) and that early in ontogeny
CD34+ CD117+ cells have long-term repopulating
activity (62). In our studies, the chimeric vector
expressed GFP in 54% CD34+ cells and 80% of
CD34+ c-Kit+ cells. The actual viral
transduction rate could be even higher because transduced Ad5GFP/F35
vector DNA was also found in GFP-negative fractions of infected cells.
This indicates that the CMV promoter used to drive GFP expression in
our vectors was not active in all transduced cells. We selected the CMV
promoter for transgene expression based on published data demonstrating
that phosphoglycerate kinase and CMV promoters allowed for efficient
transgene expression in CD34+ cells, whereas the human
T-cell leukemia virus type 1 and Rous sarcoma virus promoters were
almost inactive (6, 7). On the other hand, studies by
Watanabe et al. (74) suggest that the CMV promoter is not
active or rapidly silenced in certain CD34+ subsets. Our
data underscore this observation. Considering retroviral transduction
studies, the retroviral murine leukemia virus promoter may have been a
better candidate for transduction studies in hematopoietic cells
(5).
After having demonstrated that the Ad5GFP/F35 vector efficiently
transduced cells carrying stem cell-specific markers, the next logical
step would be to perform colony assays with presorted GFP-positive and
-negative cells. However, this assay is complicated by the fact that
infection with first-generation Ad vectors is cytotoxic and affects the
formation and growth of progenitor colonies in semi-solid cultures
(46, 74). This side effect is caused by the expression of Ad
proteins within transduced cells (41, 63, 81). Some of these
proteins (e.g., E4-orf4, pTP, and E3-11.6k) have proapoptotic
activity or induce cell cycle arrest (34, 39, 66, 72). We
plan to perform colony assays or, preferably, repopulation assays in
SCID-NOD mice with gutless vectors (68) or integrating
Ad.AAV vectors devoid of all viral genes (40) generated based on Ad5GFP/F35 chimeric capsids. Alternatively, gutless, retargeted vectors could be used to transiently express a
retroviral receptor on CD34+ cells to increase their
susceptibility to infection with retroviral vectors based on an
approach that we have published earlier (38).
Our finding that Ad5GFP/F35 can efficiently transduce hematopoietic
cells with potential stem cell capacity represents an important step
toward stable gene transfer into HSCs and gene therapy of blood
disorders. Furthermore, the virological aspects of our study contribute
to a better understanding of Ad-cell interactions.
 |
ACKNOWLEDGMENTS |
We thank Denise Farrer and Zong-Yi Li for excellent technical
assistance. We are grateful to Shelly Heimfeld (Fred Hutchinson Cancer
Research Center, Seattle, Wash.) for generously providing human
CD34+ cells. We acknowledge Jeffrey Bergelson (University
of Pennsylvania School of Medicine) for providing the antibodies
against CAR. We thank Cheryl Carlson and Dirk Steinwaerder for critical discussions.
This work was supported by NIH grants R01 CA80192 (A.L.), R21 DK55590
(A.L.), and P01 HL53750 (G.S., A.L.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division
of Medical Genetics, Department of Medicine, University of
Washington, Seattle, WA 98195. Phone: (206) 221-3973. Fax: (206)
685-8675. E-mail: lieber00{at}u.washington.edu.
 |
REFERENCES |
| 1.
|
Bailey, A., and V. Mautner.
1994.
Phylogenetic relationships among adenovirus serotypes.
Virology
205:438-452[CrossRef][Medline].
|
| 2.
|
Becker, P. S.,
S. K. Nilsson,
Z. Li,
V. M. Berrios,
M. S. Dooner,
C. L. Cooper,
C. C. Hsieh, and P. J. Quesenberry.
1999.
Adhesion receptor expression by hematopoietic cell lines and murine progenitors: modulation by cytokines and cell cycle status.
Exp. Hematol.
27:533-541[CrossRef][Medline].
|
| 3.
|
Bergelson, J. M.,
J. A. Cunningham,
G. Droguett,
E. A. Kurt-Jones,
A. Krithivas,
J. S. Hong,
M. S. Horwitz,
R. L. Crowell, and R. W. Finberg.
1997.
Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5.
Science
275:1320-1323[Abstract/Free Full Text].
|
| 4.
|
Bodine, D. M.,
T. Moritz,
R. E. Donahue,
B. D. Luskey,
S. W. Kessler,
D. I. K. Martin,
S. H. Orkin,
A. W. Nienhuis, and D. A. Williams.
1993.
Long-term in vivo expansion of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells.
Blood
82:1975-1980[Abstract/Free Full Text].
|
| 5.
|
Bregni, M.,
S. Shammah,
F. Malaffo,
M. Di Nicola, and M. Milanesi.
1998.
Adenovirus vectors for gene transduction into mobilized blood CD34+ cells.
Gene Ther.
5:465-472[CrossRef][Medline].
|
| 6.
|
Byk, T.,
H. Haddada,
W. Vainchenker, and F. Louache.
1998.
Lipofectamine and related cationic lipids strongly improve adenoviral infection efficiency of primitive human hematopoietic cells.
Hum. Gene Ther.
9:2493-2502[CrossRef][Medline].
|
| 7.
|
Case, S. S.,
M. A. Price,
C. T. Jordan,
X. J. Yu,
L. Wang,
G. Bauer,
D. L. Haas,
D. Xu,
R. Stripecke,
L. Naldini,
D. B. Kohn, and G. M. Crooks.
1999.
Stable transduction of quiescent CD34+CD38 human hematopoietic cells by HIV-1-based lentiviral vectors.
Proc. Natl. Acad. Sci. USA
96:2988-2993[Abstract/Free Full Text].
|
| 8.
|
Chartier, C.,
E. Degryse,
M. Gantzer,
A. Dieterle,
A. Pavirani, and M. Mehtali.
1996.
Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli.
J. Virol.
70:4805-4810[Abstract].
|
| 9.
|
Chen, L.,
M. Pulsipher,
D. Chen,
C. Sieff,
A. Elias,
H. A. Fine, and D. W. Kufe.
1996.
Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources.
J. Clin. Investig.
98:2539-2548[Medline].
|
| 10.
|
Chillon, M.,
A. Bosch,
J. Zabner,
L. Law,
D. Armentano,
M. Welsh, and B. L. Davidson.
1999.
Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C.
J. Virol.
73:2537-2540[Abstract/Free Full Text].
|
| 11.
|
Chroboczek, J.,
R. W. H. Ruigrok, and S. Cusack.
1995.
Adenovirus fiber, p. 163-200.
In
P. B. W. Doerfler (ed.), The molecular repertoire of adenoviruses, vol. 1. Springer-Verlag, Berlin, Germany.
|
| 12.
|
Clarke, M. F.,
I. J. Apel,
M. A. Benedict,
P. G. Eipers,
V. Sumantran,
M. Gonzalez-Garcia,
M. Doedens,
N. Fukunaga,
B. Davidson, and J. E. Dick.
1995.
A recombinant bcl-x adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells.
Proc. Natl. Acad. Sci. USA
92:11024-11028[Abstract/Free Full Text].
|
| 13.
|
Crompton, J.,
C. I. Toogood,
N. Wallis, and R. T. Hay.
1994.
Expression of a foreign epitope on the surface of the adenovirus hexon.
J. Gen. Virol.
75:133-139[Abstract/Free Full Text].
|
| 14.
|
Crooks, G. M., and D. B. Kohn.
1993.
Growth factors increase amphotropic retrovirus binding to human CD34+ bone marrow progenitor cells.
Blood
82:3290-3297[Abstract/Free Full Text].
|
| 15.
|
Defer, C.,
M.-T. Belin,
M.-C. Caillet-Boudin, and P. Boulanger.
1990.
Human adenovirus-host cell interactions: comparative study with members of subgroups B and C.
J. Virol.
64:3661-3673[Abstract/Free Full Text].
|
| 16.
|
Feldman, E.,
T. Ahmed,
J. D. Luton,
T. Farley,
K. Tani,
M. Freud,
S. Asano, and N. G. Abraham.
1997.
Adenovirus mediated alpha-interferon gene transfer into CD34+ cells and CML mononuclear cells.
Stem Cells
15:386-395[Abstract/Free Full Text].
|
| 17.
|
Flomenberg, P.,
J. Babbitt,
W. Drobyski,
R. C. Ash,
B. Camitta,
M. M. Horowitz,
N. Bunin, and J. T. Casper.
1994.
Increasing incidence of adenovirus disease in bone marrow transplant recipients.
J. Infect. Dis.
169:775-781[Medline].
|
| 18.
|
Flomenberg, P. R.,
M. Chen,
G. Munk, and M. S. Horwitz.
1987.
Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts.
J. Infect. Dis.
155:1127-1134[Medline].
|
| 19.
|
Frey, B. M.,
N. R. Hackett,
J. M. Bergelson,
R. Finberg,
R. G. Crystal,
M. A. S. Moore, and S. Rafii.
1998.
High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitors and precursor cells by adenovirus vectors.
Blood
91:2781-2792[Abstract/Free Full Text].
|
| 20.
|
Gall, J.,
A. Kass-Eisler,
L. Leinwand, and E. Falck-Pedersen.
1996.
Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralizing epitopes.
J. Virol.
70:2116-2123[Abstract].
|
| 21.
|
Goldman, M.,
Q. Su, and J. M. Wilson.
1996.
Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithelia: implication for gene therapy of cystic fibrosis.
Gene Ther.
3:811-818[Medline].
|
| 22.
|
Gonzalez, R.,
R. Verecque,
T. J. Wickham,
M. Vanrumbeke,
I. Kovesdi,
F. Bauters,
P. Fenaux, and B. Quesnel.
1999.
Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein.
Gene Ther.
6:314-320[CrossRef][Medline].
|
| 23.
|
Gruber, W. C.,
D. J. Russell, and C. Tibbetts.
1993.
Fiber gene and genomic origin of human adenovirus type 4.
Virology
196:603-611[CrossRef][Medline].
|
| 24.
|
Hitt, M. M.,
C. J. Addison, and F. J. Graham.
1997.
Human adenoviral vectors for gene transfer into mammalian cells.
Adv. Pharmacol.
40:137-205.
|
| 25.
|
Horwitz, M. S.
1996.
Adenoviruses, p. 2149-2171.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, vol. 2. Lippincott-Raven Publishers Inc., Philadelphia, Pa.
|
| 26.
|
Hsu, K.-H.,
K. Lonberg-Holm,
B. Alstein, and R. L. Crowell.
1988.
A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses.
J. Virol.
62:1647-1652[Abstract/Free Full Text].
|
| 27.
|
Huang, S.,
Y. Kamata,
Y. Takada,
Z. M. Ruggeri, and G. R. Nemerow.
1996.
Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells.
J. Virol.
70:4502-4508[Abstract].
|
| 28.
|
Huang, S.,
R. I. Endo, and G. R. Nemerow.
1995.
Upregulation of integrins v- 3 and v- 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery.
J. Virol.
69:2257-2263[Abstract].
|
| 29.
|
Ikuta, K., and I. L. Weissman.
1992.
Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation.
Proc. Natl. Acad. Sci. USA
89:1502-1506[Abstract/Free Full Text].
|
| 30.
|
Kim, M. H.,
M. Wright,
J. Deshane,
M. A. Accavitti,
A. Tilden,
M. Saleh,
W. P. Vaughan,
M. H. Carabasi,
M. D. Rogers,
R. D. Hockett,
W. E. Grizzle, and D. T. Curiel.
1997.
A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow.
Hum. Gene Ther.
8:157-170[Medline].
|
| 31.
|
Krasnykh, V.,
I. Dmitriev,
G. Mikheeva,
C. R. Miller,
N. Belousova, and D. T. Curiel.
1998.
Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob.
J. Virol.
72:1844-1852[Abstract/Free Full Text].
|
| 32.
|
Krasnykh, V. N.,
G. V. Mikheeva,
J. T. Douglas, and D. T. Curiel.
1996.
Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism.
J. Virol.
70:6839-6846[Abstract/Free Full Text].
|
| 33.
|
Kwoh, T. J.,
D. Y. Kwoh,
A. W. McCue,
G. R. Davis,
D. Patrick, and T. R. Gingeras.
1986.
Introduction and expression of the bacterial PaeR7 methylase gene in mammalian cells.
Proc. Natl. Acad. Sci. USA
83:7713-7717[Abstract/Free Full Text].
|
| 34.
|
Langer, S. J., and J. Schaak.
1996.
293 cell lines that inducibly express high level adenovirus type 5 precursor terminal protein.
Virology
221:172-179[CrossRef][Medline].
|
| 35.
|
Larochelle, A.,
J. Vormoor,
H. Hananber,
J. C. Y. Wang,
M. Bhatia,
T. Lapidot,
T. Moritz,
B. Murdoch,
X. L. Xiao,
I. Kato,
D. A. Williams, and J. E. Dick.
1996.
Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implication for gene therapy.
Nat. Med.
2:1329-1337[CrossRef][Medline].
|
| 36.
|
Legrand, V.,
D. Spehner,
Y. Schlesinger,
N. Settelen,
A. Pavirani, and M. Mehtali.
1999.
Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber.
J. Virol.
73:907-919[Abstract/Free Full Text].
|
| 37.
|
Leitner, A.,
F. Strobl,
M. Fischmeister,
K. Kurz,
O. A. Romanakis,
D. Haas,
P. Pintz,
S. Buchinger,
H. Bauer,
H. Gadner, and G. Fritsch.
1996.
Lack of DNA synthesis among CD34+ cells in cord blood and in cytokine mobilized blood.
Br. J. Haematol.
92:255-262[CrossRef][Medline].
|
| 38.
|
Lieber, A.,
M.-J. Vrancken Peeters, and M. A. Kay.
1995.
Adenovirus-mediated transfer of the amphotropic retrovirus receptor cDNA increases retroviral transduction in cultured cells.
Hum. Gene Ther.
6:5-11[Medline].
|
| 39.
|
Lieber, A.,
C.-Y. He,
L. Meuse,
C. Himeda,
C. Wilson, and M. A. Kay.
1998.
Inhibition of NF- B activation in combination with Bcl-2 expression allows for persistence of first-generation adenovirus vectors in mouse livers.
J. Virol.
72:9267-9277[Abstract/Free Full Text].
|
| 40.
|
Lieber, A.,
D. Steinwaerder,
C. A. Carlson,
Z. Y. Li, and M. A. Kay.
1999.
Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes.
J. Virol.
73:9314-9324[Abstract/Free Full Text].
|
| 41.
|
Lieber, A.,
C.-Y. He,
I. Kirillova, and M. A. Kay.
1996.
Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.
J. Virol.
70:8944-8960[Abstract].
|
| 42.
|
Maizel, J. V.,
D. White, and M. D. Scharff.
1968.
The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7a, and 12.
Virology
36:115-125[CrossRef][Medline].
|
| 43.
|
Mathias, P.,
T. Wickham,
M. Moore, and G. Nemerow.
1994.
Multiple adenovirus serotypes use -v integrins for infection.
J. Virol.
68:6811-6814[Abstract/Free Full Text].
|
| 44.
|
McGuckin, C. P.,
W. M. Liu,
E. C. Gordon-Smith, and M. R. Uhr.
1996.
A novel approach to investigating the erythroid lineage, using both receptor analysis and haemaglobin detection.
Br. J. Haematol.
95:457-460[CrossRef][Medline].
|
| 45.
|
Michael, S. I.,
J. S. Hong,
D. T. Curiel, and J. A. Engler.
1995.
Addition of a short peptide ligand to the adenovirus fiber protein.
Gene Ther.
2:660-668[Medline].
|
| 46.
|
Mitani, K.,
F. L. Graham, and C. T. Caskey.
1994.
Transduction of human bone marrow by adenoviral vectors.
Hum. Gene Ther.
5:941-948[Medline].
|
| 47.
|
Mittereder, N.,
K. L. March, and B. C. Trapnell.
1996.
Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.
J. Virol.
70:7498-7509[Abstract].
|
| 48.
|
Miyazawa, N.,
P. L. Leopold,
N. R. Hackett,
B. Ferris,
S. Worgall,
E. Falck-Pedersen, and R. Crystal.
1999.
Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors.
J. Virol.
73:6056-6065[Abstract/Free Full Text].
|
| 49.
|
Mizuguchi, H., and M. A. Kay.
1998.
Efficient construction of recombinant adenovirus vectors by an improved in vitro ligation method.
Hum. Gene Ther.
9:2577-2583[CrossRef][Medline].
|
| 50.
|
Neering, S. J.,
S. F. Hardy,
D. Minamoto,
S. K. Spratt, and C. T. Jordan.
1996.
Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors.
Blood
88:1147-1155[Abstract/Free Full Text].
|
| 51.
|
Nelson, J., and M. A. Kay.
1997.
Persistence of recombinant adenovirus in vivo is not dependent on vector replication.
J. Virol.
71:8902-8907[Abstract].
|
| 52.
|
Neu, S.,
A. Geiselhart,
S. Kuci,
F. Baur,
D. Niethammer, and R. Handgretinger.
1996.
Isolation and phenotypic characterization of CD117 positive cells.
Leuk. Res.
20:960-971.
|
| 53.
|
Orlic, D.,
L. J. Girard,
S. M. Anderson,
B. K. Q. Do,
N. E. Seidel,
C. T. Jordan, and D. M. Bodine.
1997.
Transduction efficiency of cell lines and hematopoietic stem cells correlates with retrovirus receptor mRNA levels.
Stem Cells
15:23-28.
|
| 54.
|
Papayannopoulou, T., and C. Craddock.
1997.
Homing and trafficking of hematopoietic progenitor cells.
Acta Haematol.
97:97-104[Medline].
|
| 55.
|
Pring Akerblom, P.,
A. Heim, and F. J. Trijssenaar.
1998.
Molecular characterization of hemagglutination domains on the fibers of subgenus D adenoviruses.
J. Virol.
72:2297-2304[Abstract/Free Full Text].
|
| 56.
|
Qui, C.,
M. B. De Young,
A. Finn, and D. A. Dichek.
1998.
Cationic liposomes enhance adenovirus entry via a pathway independent of the fiber receptor and v integrins.
Hum. Gene Ther.
9:507-520[Medline].
|
| 57.
|
Roberts, A. W., and D. Metcalf.
1995.
Noncycling state of peripheral blood progenitors cells mobilized by granulocyte colony-stimulating factor and other cytokines.
Blood
86:1600-1605[Abstract/Free Full Text].
|
| 58.
|
Rodriguez, E., and E. Everitt.
1999.
Adenovirus cellular receptor site recirculation of HeLa cells upon receptor mediated endocytolysis is not low pH dependent.
Arch. Virol.
144:787-795[CrossRef][Medline].
|
| 59.
|
Roelvink, P. W.,
J. Kovesdi, and T. J. Wickham.
1996.
Comparative analysis of adenovirus fiber-cell interaction: adenovirus type 2 (Ad2) and Ad9 utilize the same fiber receptor but use different binding strategies for attachment.
J. Virol.
70:7614-7621[Abstract].
|
| 60.
|
Roelvink, P. W.,
A. Lizonova,
J. G. Lee,
Y. Li,
J. M. Bergelson,
R. W. Finberg,
D. E. Brough,
I. Kovesdi, and T. J. Wickham.
1998.
The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F.
J. Virol.
72:7909-7915[Abstract/Free Full Text].
|
| 61.
|
Roy, V., and C. M. Verfaillie.
1999.
Expression and function of cell adhesion molecules on fetal liver, cord blood, and bone marrow hematopoietic progenitors; implications for anatomical localization and developmental stage specific regulation of hematopoiesis.
Exp. Hematol.
27:302-312[CrossRef][Medline].
|
| 62.
|
Sanchez, M. J.,
A. Holmes,
C. Miles, and E. Dzierzak.
1996.
Characterization of the first definitive hematopoietic stem cells in the AGM and liver of mouse embryo.
Immunity
5:513-525[CrossRef][Medline].
|
| 63.
|
Schiedner, G.,
N. Morral,
R. J. Parks,
Y. Wu,
S. C. Koopmans,
C. Langston,
F. L. Graham,
A. L. Beaudet, and S. Kochanek.
1998.
Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.
Nat. Genet.
18:180-183[CrossRef][Medline].
|
| 64.
|
Shenk, T.
1996.
Adenoviridae, p. 2111-2148.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, vol. 2. Lippincott-Raven Publisher, Philadelphia, Pa.
|
| 65.
|
Shields, A. F.,
R. C. Hackman,
K. H. Fife,
L. Corey, and J. D. Meyers.
1985.
Adenovirus infections in patients undergoing bone-marrow transplantations.
N. Eng. J. Med.
312:529-533[Abstract].
|
| 66.
|
Shtrichman, R., and T. Kleinberger.
1998.
Adenovirus type 5 E4 open reading frame 4 protein induces apoptosis in transformed cells.
J. Virol.
72:2975-2983[Abstract/Free Full Text].
|
| 67.
|
Simmons, P. J.,
G. W. Aylett,
S. Niuatta,
J. B. To,
C. A. Juttner, and J. K. Ashman.
1994.
c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture.
Exp. Hematol.
22:157-165[Medline].
|
| 68.
|
Steinwaerder, D. S.,
C. A. Carlson, and A. Lieber.
1999.
Generation of adenoviral vectors devoid of all viral genes by recombination between inverted repeats.
J. Virol.
73:9303-9313[Abstract/Free Full Text].
|
| 69.
|
Stevenson, S. C.,
M. Rollence,
B. White,
L. Wever, and A. McClelland.
1995.
Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain.
J. Virol.
69:2850-2857[Abstract].
|
| 70.
|
Stevenson, S. C.,
M. Rollence,
J. Marshall-Neff, and A. McClelland.
1997.
Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein.
J. Virol.
71:4782-4790[Abstract].
|
| 71.
|
Tiemessen, C. T., and A. H. Kidd.
1995.
The subgroup F adenoviruses.
J. Gen. Virol.
76:481-497[Abstract/Free Full Text].
|
| 72.
|
Tollefson, A. E.,
A. Scaria,
T. W. Hermiston,
J. S. Ryerse,
L. J. Wold, and W. S. M. Wold.
1996.
The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells.
J. Virol.
70:2296-2306[Abstract].
|
| 73.
|
Tomko, R. P.,
R. Xu, and L. Philipson.
1997.
HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses.
Proc. Natl. Acad. Sci. USA
94:3352-3356[Abstract/Free Full Text].
|
| 74.
|
Watanabe, T.,
C. Kuszynski,
K. Ino,
D. G. Heiman,
H. M. Shephard,
Y. Yasul,
D. C. Maneval, and J. E. Talmadge.
1996.
Gene transfer into human bone marrow hematopoietic cells mediated by adenovirus vectors.
Blood
87:5032-5039[Abstract/Free Full Text].
|
| 75.
|
Watkins, S. J.,
V. V. Mesyanzhinov,
L. P. Kurochkina, and R. E. Hawkins.
1997.
The antibody approach to viral targeting-specific and enhanced adenoviral gene delivery.
Gene Ther.
4:1004-1012[CrossRef][Medline].
|
| 76.
|
Wickham, T.,
P. Roelvink,
D. Brough, and I. Kovesdi.
1996.
Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types.
Nat. Biotechnol.
14:1570-1573[CrossRef][Medline].
|
| 77.
|
Wickham, T. J.,
P. Mathias,
D. A. Cheresh, and G. R. Nemerow.
1993.
Integrins alpha-v-beta3 and alpha-v-beta5 promote adenovirus internalization but not virus attachment.
Cell
73:309-319[CrossRef][Medline].
|
| 78.
|
Wickham, T. J.,
D. M. Segal,
P. W. Roelvink,
M. E. Carrion,
G. M. Lizonova, and I. Kovesdi.
1996.
Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies.
J. Virol.
70:6831-6838[Abstract/Free Full Text].
|
| 79.
|
Wickham, T. J.,
M. E. Carrion, and I. Kovesdi.
1995.
Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs.
Gene Ther.
2:750-756[Medline].
|
| 80.
|
Wroblewski, J. M.,
L. T. Lay,
G. Vant Zant,
G. Phillips,
P. Seth,
D. Curiel, and T. C. Meeker.
1996.
Selective elimination of contaminating malignant cells from hematopoietic stem cell autografts using recombinant adenovirus.
Cancer Gene Ther.
3:257-264[Medline].
|
| 81.
|
Yang, Y.,
F. A. Nunes,
K. Berencsi,
E. E. Furth,
E. Gonczol, and J. M. Wilson.
1994.
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
Proc. Natl. Acad. Sci. USA
91:4407-4411[Abstract/Free Full Text].
|
| 82.
|
Zabner, J.,
A. Puga,
P. Freimuth, and M. J. Welsh.
1997.
Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection.
J. Clin. Investig.
100:1144-1149[Medline].
|
Journal of Virology, March 2000, p. 2567-2583, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Strauss, R., Sova, P., Liu, Y., Li, Z. Y., Tuve, S., Pritchard, D., Brinkkoetter, P., Moller, T., Wildner, O., Pesonen, S., Hemminki, A., Urban, N., Drescher, C., Lieber, A.
(2009). Epithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic Adenoviruses. Cancer Res.
69: 5115-5125
[Abstract]
[Full Text]
-
Wang, H., Liu, Y., Li, Z., Tuve, S., Stone, D., Kalyushniy, O., Shayakhmetov, D., Verlinde, C. L. M., Stehle, T., McVey, J., Baker, A., Peng, K.-W., Roffler, S., Lieber, A.
(2008). In Vitro and In Vivo Properties of Adenovirus Vectors with Increased Affinity to CD46. J. Virol.
82: 10567-10579
[Abstract]
[Full Text]
-
Suzuki, K., Mitsui, K., Aizawa, E., Hasegawa, K., Kawase, E., Yamagishi, T., Shimizu, Y., Suemori, H., Nakatsuji, N., Mitani, K.
(2008). Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors. Proc. Natl. Acad. Sci. USA
105: 13781-13786
[Abstract]
[Full Text]
-
Stone, D., Liu, Y., Li, Z.-Y., Strauss, R., Finn, E. E., Allen, J. M., Chamberlain, J. S., Lieber, A.
(2008). Biodistribution and Safety Profile of Recombinant Adeno-Associated Virus Serotype 6 Vectors following Intravenous Delivery. J. Virol.
82: 7711-7715
[Abstract]
[Full Text]
-
Blyn, L. B., Hall, T. A., Libby, B., Ranken, R., Sampath, R., Rudnick, K., Moradi, E., Desai, A., Metzgar, D., Russell, K. L., Freed, N. E., Balansay, M., Broderick, M. P., Osuna, M. A., Hofstadler, S. A., Ecker, D. J.
(2008). Rapid Detection and Molecular Serotyping of Adenovirus by Use of PCR Followed by Electrospray Ionization Mass Spectrometry. J. Clin. Microbiol.
46: 644-651
[Abstract]
[Full Text]
-
Li, X., Liu, Y.-H., Lee, S.-J., Gardner, T. A., Jeng, M.-H., Kao, C.
(2008). Prostate-Restricted Replicative Adenovirus Expressing Human Endostatin-Angiostatin Fusion Gene Exhibiting Dramatic Antitumor Efficacy. Clin. Cancer Res.
14: 291-299
[Abstract]
[Full Text]
-
Wang, H., Liaw, Y.-C., Stone, D., Kalyuzhniy, O., Amiraslanov, I., Tuve, S., Verlinde, C. L. M. J., Shayakhmetov, D., Stehle, T., Roffler, S., Lieber, A.
(2007). Identification of CD46 Binding Sites within the Adenovirus Serotype 35 Fiber Knob. J. Virol.
81: 12785-12792
[Abstract]
[Full Text]
-
Di Paolo, N. C., Kalyuzhniy, O., Shayakhmetov, D. M.
(2007). Fiber Shaft-Chimeric Adenovirus Vectors Lacking the KKTK Motif Efficiently Infect Liver Cells In Vivo. J. Virol.
81: 12249-12259
[Abstract]
[Full Text]
-
Wohlfahrt, M. E., Beard, B. C., Lieber, A., Kiem, H.-P.
(2007). A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma Models. Cancer Res.
67: 8783-8790
[Abstract]
[Full Text]
-
Stone, D., Liu, Y., Shayakhmetov, D., Li, Z.-Y., Ni, S., Lieber, A.
(2007). Adenovirus-Platelet Interaction in Blood Causes Virus Sequestration to the Reticuloendothelial System of the Liver. J. Virol.
81: 4866-4871
[Abstract]
[Full Text]
-
Iacobelli-Martinez, M., Nemerow, G. R.
(2007). Preferential Activation of Toll-Like Receptor Nine by CD46-Utilizing Adenoviruses. J. Virol.
81: 1305-1312
[Abstract]
[Full Text]
-
Tuve, S., Wang, H., Ware, C., Liu, Y., Gaggar, A., Bernt, K., Shayakhmetov, D., Li, Z., Strauss, R., Stone, D., Lieber, A.
(2006). A New Group B Adenovirus Receptor Is Expressed at High Levels on Human Stem and Tumor Cells. J. Virol.
80: 12109-12120
[Abstract]
[Full Text]
-
Wang, H., Lieber, A.
(2006). A Helper-Dependent Capsid-Modified Adenovirus Vector Expressing Adeno-Associated Virus Rep78 Mediates Site-Specific Integration of a 27-Kilobase Transgene Cassette. J. Virol.
80: 11699-11709
[Abstract]
[Full Text]
-
Jaras, M., Edqvist, A., Rebetz, J., Salford, L. G., Widegren, B., Fan, X.
(2006). Human short-term repopulating cells have enhanced telomerase reverse transcriptase expression. Blood
108: 1084-1091
[Abstract]
[Full Text]
-
Pichiorri, F., Trapasso, F., Palumbo, T., Aqeilan, R. I., Drusco, A., Blaser, B. W., Iliopoulos, D., Caligiuri, M. A., Huebner, K., Croce, C. M.
(2006). Preclinical Assessment of FHIT Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35.. Clin. Cancer Res.
12: 3494-3501
[Abstract]
[Full Text]
-
Reddy, P. S., Ganesh, S., Yu, D.-C.
(2006). Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses.. Clin. Cancer Res.
12: 2869-2878
[Abstract]
[Full Text]
-
Knaan-Shanzer, S., van de Watering, M. J.M., van der Velde, I., Goncalves, M. A.F.V., Valerio, D., de Vries, A. A.F.
(2005). Endowing Human Adenovirus Serotype 5 Vectors with Fiber Domains of Species B Greatly Enhances Gene Transfer into Human Mesenchymal Stem Cells. Stem Cells
23: 1598-1607
[Abstract]
[Full Text]
-
Wang, H., Shayakhmetov, D. M., Leege, T., Harkey, M., Li, Q., Papayannopoulou, T., Stamatoyannopolous, G., Lieber, A.
(2005). A Capsid-Modified Helper-Dependent Adenovirus Vector Containing the {beta}-Globin Locus Control Region Displays a Nonrandom Integration Pattern and Allows Stable, Erythroid-Specific Gene Expression. J. Virol.
79: 10999-11013
[Abstract]
[Full Text]
-
Fleischli, C., Verhaagh, S., Havenga, M., Sirena, D., Schaffner, W., Cattaneo, R., Greber, U. F., Hemmi, S.
(2005). The Distal Short Consensus Repeats 1 and 2 of the Membrane Cofactor Protein CD46 and Their Distance from the Cell Membrane Determine Productive Entry of Species B Adenovirus Serotype 35. J. Virol.
79: 10013-10022
[Abstract]
[Full Text]
-
Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z.-Y., Lieber, A.
(2005). Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity. J. Virol.
79: 7478-7491
[Abstract]
[Full Text]
-
Gaggar, A., Shayakhmetov, D. M., Liszewski, M. K., Atkinson, J. P., Lieber, A.
(2005). Localization of Regions in CD46 That Interact with Adenovirus. J. Virol.
79: 7503-7513
[Abstract]
[Full Text]
-
Shayakhmetov, D. M., Li, Z.-Y., Ni, S., Lieber, A.
(2005). Interference with the IL-1-Signaling Pathway Improves the Toxicity Profile of Systemically Applied Adenovirus Vectors. J. Immunol.
174: 7310-7319
[Abstract]
[Full Text]
-
Bernt, K. M., Ni, S., Tieu, A.-T., Lieber, A.
(2005). Assessment of a Combined, Adenovirus-Mediated Oncolytic and Immunostimulatory Tumor Therapy. Cancer Res.
65: 4343-4352
[Abstract]
[Full Text]
-
Stone, D., Ni, S., Li, Z.-Y., Gaggar, A., DiPaolo, N., Feng, Q., Sandig, V., Lieber, A.
(2005). Development and Assessment of Human Adenovirus Type 11 as a Gene Transfer Vector. J. Virol.
79: 5090-5104
[Abstract]
[Full Text]
-
Shayakhmetov, D. M., Eberly, A. M., Li, Z.-Y., Lieber, A.
(2005). Deletion of Penton RGD Motifs Affects the Efficiency of both the Internalization and the Endosome Escape of Viral Particles Containing Adenovirus Serotype 5 or 35 Fiber Knobs. J. Virol.
79: 1053-1061
[Abstract]
[Full Text]
-
Yotnda, P., Savoldo, B., Charlet-Berguerand, N., Rooney, C., Brenner, M.
(2004). Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood
104: 2272-2280
[Abstract]
[Full Text]
-
Leen, A. M., Sili, U., Vanin, E. F., Jewell, A. M., Xie, W., Vignali, D., Piedra, P. A., Brenner, M. K., Rooney, C. M.
(2004). Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood
104: 2432-2440
[Abstract]
[Full Text]
-
Shayakhmetov, D. M., Li, Z.-Y., Gaggar, A., Gharwan, H., Ternovoi, V., Sandig, V., Lieber, A.
(2004). Genome Size and Structure Determine Efficiency of Postinternalization Steps and Gene Transfer of Capsid-Modified Adenovirus Vectors in a Cell-Type-Specific Manner. J. Virol.
78: 10009-10022
[Abstract]
[Full Text]
-
Skog, J., Edlund, K., Widegren, B., Salford, L. G., Wadell, G., Mei, Y.-F.
(2004). Efficient internalization into low-passage glioma cell lines using adenoviruses other than type 5: an approach for improvement of gene delivery to brain tumours. J. Gen. Virol.
85: 2627-2638
[Abstract]
[Full Text]
-
Mallam, J. N., Hurwitz, M. Y., Mahoney, T., Chevez-Barrios, P., Hurwitz, R. L.
(2004). Efficient Gene Transfer into Retinal Cells Using Adenoviral Vectors: Dependence on Receptor Expression. IOVS
45: 1680-1687
[Abstract]
[Full Text]
-
Shayakhmetov, D. M., Li, Z.-Y., Ni, S., Lieber, A.
(2004). Analysis of Adenovirus Sequestration in the Liver, Transduction of Hepatic Cells, and Innate Toxicity after Injection of Fiber-Modified Vectors. J. Virol.
78: 5368-5381
[Abstract]
[Full Text]
-
Sirena, D., Lilienfeld, B., Eisenhut, M., Kalin, S., Boucke, K., Beerli, R. R., Vogt, L., Ruedl, C., Bachmann, M. F., Greber, U. F., Hemmi, S.
(2004). The Human Membrane Cofactor CD46 Is a Receptor for Species B Adenovirus Serotype 3. J. Virol.
78: 4454-4462
[Abstract]
[Full Text]
-
Moldenhauer, A., Shieh, J-H, Pruss, A., Salama, A., Moore, M.A.S.
(2004). Tumor Necrosis Factor Alpha Enhances the Adenoviral Transduction of CD34+ Hematopoietic Progenitor Cells. Stem Cells
22: 283-291
[Abstract]
[Full Text]
-
Korokhov, N., Mikheeva, G., Krendelshchikov, A., Belousova, N., Simonenko, V., Krendelshchikova, V., Pereboev, A., Kotov, A., Kotova, O., Triozzi, P. L., Aldrich, W. A., Douglas, J. T., Lo, K.-M., Banerjee, P. T., Gillies, S. D., Curiel, D. T., Krasnykh, V.
(2003). Targeting of Adenovirus via Genetic Modification of the Viral Capsid Combined with a Protein Bridge. J. Virol.
77: 12931-12940
[Abstract]
[Full Text]
-
Goldsmith, M. E., Kitazono, M., Fok, P., Aikou, T., Bates, S., Fojo, T.
(2003). The Histone Deacetylase Inhibitor FK228 Preferentially Enhances Adenovirus Transgene Expression in Malignant Cells. Clin. Cancer Res.
9: 5394-5401
[Abstract]
[Full Text]
-
Shayakhmetov, D. M., Li, Z.-Y., Ternovoi, V., Gaggar, A., Gharwan, H., Lieber, A.
(2003). The Interaction between the Fiber Knob Domain and the Cellular Attachment Receptor Determines the Intracellular Trafficking Route of Adenoviruses. J. Virol.
77: 3712-3723
[Abstract]
[Full Text]
-
Zhang, L.-Q., Mei, Y.-F., Wadell, G.
(2003). Human adenovirus serotypes 4 and 11 show higher binding affinity and infectivity for endothelial and carcinoma cell lines than serotype 5. J. Gen. Virol.
84: 687-695
[Abstract]
[Full Text]
-
Nakamura, T., Sato, K., Hamada, H.
(2003). Reduction of Natural Adenovirus Tropism to the Liver by both Ablation of Fiber-Coxsackievirus and Adenovirus Receptor Interaction and Use of Replaceable Short Fiber. J. Virol.
77: 2512-2521
[Abstract]
[Full Text]
-
Segerman, A., Arnberg, N., Erikson, A., Lindman, K., Wadell, G.
(2002). There Are Two Different Species B Adenovirus Receptors: sBAR, Common to Species B1 and B2 Adenoviruses, and sB2AR, Exclusively Used by Species B2 Adenoviruses. J. Virol.
77: 1157-1162
[Abstract]
[Full Text]
-
Bernt, K. M., Steinwaerder, D. S., Ni, S., Li, Z.-Y., Roffler, S. R., Lieber, A.
(2002). Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer Res.
62: 6089-6098
[Abstract]
[Full Text]
-
Bernt, K., Liang, M., Ye, X., Ni, S., Li, Z.-Y., Ye, S. L., Hu, F., Lieber, A.
(2002). A New Type of Adenovirus Vector That Utilizes Homologous Recombination To Achieve Tumor-Specific Replication. J. Virol.
76: 10994-11002
[Abstract]
[Full Text]
-
Belousova, N., Krendelchtchikova, V., Curiel, D. T., Krasnykh, V.
(2002). Modulation of Adenovirus Vector Tropism via Incorporation of Polypeptide Ligands into the Fiber Protein. J. Virol.
76: 8621-8631
[Abstract]
[Full Text]
-
Kitazono, M., Rao, V. K., Robey, R., Aikou, T., Bates, S., Fojo, T., Goldsmith, M. E.
(2002). Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Blood
99: 2248-2251
[Abstract]
[Full Text]
-
Ring, C. J. A.
(2002). Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol.
83: 491-502
[Abstract]
[Full Text]
-
Seki, T., Dmitriev, I., Kashentseva, E., Takayama, K., Rots, M., Suzuki, K., Curiel, D. T.
(2002). Artificial Extension of the Adenovirus Fiber Shaft Inhibits Infectivity in Coxsackievirus and Adenovirus Receptor-Positive Cell Lines. J. Virol.
76: 1100-1108
[Abstract]
[Full Text]
-
Shayakhmetov, D. M., Carlson, C. A., Stecher, H., Li, Q., Stamatoyannopoulos, G., Lieber, A.
(2002). A High-Capacity, Capsid-Modified Hybrid Adenovirus/Adeno-Associated Virus Vector for Stable Transduction of Human Hematopoietic Cells. J. Virol.
76: 1135-1143
[Abstract]
[Full Text]
-
Shayakhmetov, D. M., Li, Z.-Y., Ni, S., Lieber, A.
(2002). Targeting of Adenovirus Vectors to Tumor Cells Does Not Enable Efficient Transduction of Breast Cancer Metastases. Cancer Res.
62: 1063-1068
[Abstract]
[Full Text]
-
Law, L. K., Davidson, B. L.
(2002). Adenovirus Serotype 30 Fiber Does Not Mediate Transduction via the Coxsackie-Adenovirus Receptor. J. Virol.
76: 656-661
[Abstract]
[Full Text]
-
Farina, S. F., Gao, G.-p., Xiang, Z. Q., Rux, J. J., Burnett, R. M., Alvira, M. R., Marsh, J., Ertl, H. C. J., Wilson, J. M.
(2001). Replication-Defective Vector Based on a Chimpanzee Adenovirus. J. Virol.
75: 11603-11613
[Abstract]
[Full Text]
-
Tan, P. K., Michou, A.-I., Bergelson, J. M., Cotten, M.
(2001). Defining CAR as a cellular receptor for the avian adenovirus CELO using a genetic analysis of the two viral fibre proteins. J. Gen. Virol.
82: 1465-1472
[Abstract]
[Full Text]
-
Rea, D., Havenga, M. J. E., van den Assem, M., Sutmuller, R. P. M., Lemckert, A., Hoeben, R. C., Bout, A., Melief, C. J. M., Offringa, R.
(2001). Highly Efficient Transduction of Human Monocyte-Derived Dendritic Cells with Subgroup B Fiber-Modified Adenovirus Vectors Enhances Transgene-Encoded Antigen Presentation to Cytotoxic T Cells. J. Immunol.
166: 5236-5244
[Abstract]
[Full Text]
-
Havenga, M. J. E., Lemckert, A. A. C., Grimbergen, J. M., Vogels, R., Huisman, L. G. M., Valerio, D., Bout, A., Quax, P. H. A.
(2001). Improved Adenovirus Vectors for Infection of Cardiovascular Tissues. J. Virol.
75: 3335-3342
[Abstract]
[Full Text]
-
Ebbinghaus, C., Al-Jaibaji, A., Operschall, E., Schöffel, A., Peter, I., Greber, U. F., Hemmi, S.
(2001). Functional and Selective Targeting of Adenovirus to High-Affinity Fc{gamma} Receptor I-Positive Cells by Using a Bispecific Hybrid Adapter. J. Virol.
75: 480-489
[Abstract]
[Full Text]
-
Shayakhmetov, D. M., Lieber, A.
(2000). Dependence of Adenovirus Infectivity on Length of the Fiber Shaft Domain. J. Virol.
74: 10274-10286
[Abstract]
[Full Text]